Diabetes Mellitus

For the Ethiopian Health Center Team

Dereje Abebe, Yayehirad Tassachew, Jemal Adem, Nejmudin Reshad, and Sintayehu Delelegn

Debub University

In collaboration with the Ethiopia Public Health Training Initiative, The Carter Center, the Ethiopia Ministry of Health, and the Ethiopia Ministry of Education

2005
ACKNOWLEDGMENTS

The authors are grateful to The Carter Center for its financial, material, moral and expert assistance without which it would have been impossible to develop this module.

We could like to extend our gratitude to our university /Health Science College/ for keeping the atmosphere conductive for the preparation of this module.

Finally, it is our pleasure to acknowledge all those, who have directly and/or indirectly provided us with administrative and logistic support that ultimately facilitated the development and preparation of the module.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acknowledgments</td>
<td>i</td>
</tr>
<tr>
<td>Table of contents</td>
<td>ii</td>
</tr>
<tr>
<td><strong>UNIT ONE: Introduction</strong></td>
<td>1</td>
</tr>
<tr>
<td>1.1 Purpose and use of the module</td>
<td>1</td>
</tr>
<tr>
<td>1.2. Direction for using the module</td>
<td>1</td>
</tr>
<tr>
<td><strong>UNIT TWO: The core module</strong></td>
<td>2</td>
</tr>
<tr>
<td>2.1 Pre and post tests</td>
<td>2</td>
</tr>
<tr>
<td>2.2 Significance and brief description about measles</td>
<td>9</td>
</tr>
<tr>
<td>2.3 Learning objectives</td>
<td>9</td>
</tr>
<tr>
<td>2.4 Learning Activity</td>
<td>9</td>
</tr>
<tr>
<td>Definition</td>
<td>11</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>9</td>
</tr>
<tr>
<td>Clinical features</td>
<td>13</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>14</td>
</tr>
<tr>
<td>Management</td>
<td>16</td>
</tr>
<tr>
<td>Prevention and control</td>
<td>21</td>
</tr>
<tr>
<td><strong>UNIT THREE: Satellite modules</strong></td>
<td>36</td>
</tr>
<tr>
<td>3.1 Satellite module for Public Health Officers</td>
<td>36</td>
</tr>
<tr>
<td>3.2 Satellite module for Public Health Nurses</td>
<td>43</td>
</tr>
<tr>
<td>3.3 Satellite module for Medical Laboratory Technologists</td>
<td>70</td>
</tr>
<tr>
<td>3.4 Satellite module for Environmental Health Officers</td>
<td>105</td>
</tr>
<tr>
<td>Satellite module for Health Service Extension workers</td>
<td>111</td>
</tr>
<tr>
<td>Table – Knowledge</td>
<td>123</td>
</tr>
<tr>
<td>Table – Attitude</td>
<td>124</td>
</tr>
<tr>
<td>Table – Practice</td>
<td>125</td>
</tr>
<tr>
<td>Reference</td>
<td>126</td>
</tr>
<tr>
<td>Key answers</td>
<td>127</td>
</tr>
</tbody>
</table>
UNIT ONE
INTRODUCTION

1.1 Purposes and Use of the Module
This module is intended to serve as a general learning material for diabetes mellitus by
the health center team.
This module can also be used by other categories of health professionals. It should be
kept in mind, though, that it is not a substitute for standard textbooks.

1.2 Directions for Using the Module
Before starting to read this module, please follow the instruction given below.

- Start with the pre-test before going through the core module.
- Use a separate sheet of paper to write your answers. The pretest contains two
  parts: Part One and Part Two.
  - Part one contains common questions to be attempted by all categories of
    the health center team.
  - Part two questions are prepared for the specific categories; health officers,
    nurses, environmental health technologists, and medical laboratory
    technologists. Select and answer questions that apply to you.
- Having gone through the core module, proceed to read the satellite module that
  corresponds to your profession of interest.
- Study the task analysis for the health center team members in comparison with
  that of your own.
UNIT TWO
CORE MODULE

2.1 Pre test
Answer the questions as appropriate on a separate answer sheet.

2.1.1 Pretest for all categories of the health center team
Write true or false for questions 1-3 and give short answers for questions 4 through 8.
1. The prevalence of diabetes mellitus is declining in recent years due to improved management of cases.
2. Diabetes mellitus is a curable illness.
3. Diabetes mellitus is a disease of adults.
4. How is diabetes mellitus classified currently?
5. What are the laboratory tests that could be carried out to make a diagnosis of diabetes mellitus?
6. What are the acute metabolic complications of diabetes mellitus?
7. Compare and contrast type 1 and type 2 diabetes mellitus.
8. Mention the goals of long-term treatment of patients with diabetes mellitus.

2.1.2 Pretest for Specific Categories of the Health Center Team
2.1.2.1 Health Officers
1. What are the salient features in the clinical evaluation of a patient suspected to have diabetes that aid you in labeling him/her as having type 1 or type 2 diabetes mellitus?
2. List some oral antihyperglycemic agents that are in common use.
3. What are the signs and symptoms that may be seen in a patient with hypoglycemia? What should the first step be in managing a known diabetic when he/she presents with loss of consciousness in the absence of a laboratory facility that could help you determine the random blood sugar?
**2.1.2.2 Bsc Nurses**

Answer the following questions on the separate sheet.

1. Which of the following is the best time for short acting insulin administration?
   
   A. Morning before meal  
   B. Morning after meal  
   C. At any time through a day  
   D. Evening only

2. Which action would be **inappropriate** to include in diabetic teaching plan?
   
   A. Changing position hourly to increase circulation  
   B. Inspect legs and feet’s daily for any change  
   C. Keep legs elevated on two pillows  
   D. Keep insulin not in use in the refrigerator

3. Which statement is **true** regarding diabetes?
   
   A. Diabetes is an acute disorder that responds only to insulin treatment  
   B. Diabetes is chronic disorder that responds only to insulin treatment  
   C. Diabetes is an abnormality of carbohydrate, fat, protein metabolism  
   D. All of the above

4. One of the following is **not** the site for subcutaneous injection during management of diabetes mellitus.
   
   A. Outer aspects of the upper arms  
   B. Anterior thigh  
   C. Abdomen  
   D. All  
   E. None

5. A boy age 7 recently was diagnosed with type 1 diabetes mellitus. He takes NPH and regular insulin. His mother asks the nurse if he can go on an afternoon foot ball playing during an upcoming weekend. Which response by the Nurse would be the best?
   
   A. He should have a snack, such as cheese, sandwich and a glass of milk, an hour before the play and should carry a fast acting source of glucose
B. He should not go on to play because the possible side effects of extraordinary activates are just unpredictable
C. He should increase morning dosage of NPH insulin by approximately 1/3 to cover the increased metabolic rate during the play
D. B and C

6. WHO diagnostic criteria for DM in non pregnant women and male adults is
   A. Random blood sugar >140mg/dl
   B. Random blood sugar >110mg/dl
   C. Random blood sugar >200mg/dl
   D. Random blood sugar >180ml/dl

7. The majority of calories of a diabetic patient should be obtained from
   A. Complex carbohydrate
   B. Simple carbohydrate
   C. Proteins
   D. Fats
   E. C&D

8. There seems to be a positive association between type 2 DM and
   A. Hypotension
   B. Kidney dysfunction
   C. Obesity
   D. Sex
   E. None

9. The nurse should encourage exercise in a diabetic patients because it
   A. Decreases total triglycerid level
   B. Improves insulin utilization
   C. Lowers blood glucose
   D. Accomplishes all of the above
   E. None
Part II True / False questions

a. There is no cure for Diabetes T/F
b. Glucose is mainly made in the kidney T/F
c. ‘A’ cells in the Islets of Langerhans produce insulin T/F
d. Many complications of Diabetes are avoidable T/F
e. Diabetes is more common in obese people T/F
f. Glucagon is used to treat hyperglycemia T/F
g. In infections the blood sugar level goes down T/F
h. Raised blood pressure should always be treated in the
i. Diabetic patient T/F
j. Diabetics should routinely test their urine for ketones T/F
k. Ketoacidosis and vomiting in a diabetic is a life-threatening situation T/F
l. Short-acting insulin acts for about 1 hour T/F
m. The main problem to address in diabetes is the normalization of blood sugar levels T/F
n. Blisters on a diabetic foot are often painless T/F
o. All available insulin’s contain 100U per ml T/F
p. Refined carbohydrates are unrestricted in a diabetic diet T/F
q. Fiber is unrestricted in a diabetic patient T/F
r. Hypertension is only important when proteinuria is present T/F
s. The ischaemic foot is characterized by absent pulses T/F
t. Diabetic Autonomic Neuropathy can cause impotence T/F
u. The feet should be checked at every follow up visit T/F
v. Infection can cause loss of glycaemic control T/F

Part II Case study

10. Ato Kebede, a newly diagnosed type1 patient is admitted to the medical ward. You further assessed him and found that patient has polyphagia polydypsia and weight loss. The physician ordered lente insulin for him.
A. You planned to teach Ato kebede about self-injection of insulin. What are the important points that should be included in your teaching plan?

B. One of the acute complications of diabetic mellitus is hypoglycemia. What are the causes of hypoglycemia in a diabetic patient like Ato Kebede?

C. How do you explain the signs of hypoglycemia for Ato Kebede?

D. How do you prevent the complication of hypoglycemia?

E. It is known that majority of lower extremity amputation are performed in a diabetic patient like Ato kebede. What are the diabetic complications contributing to foot infections?

F. Mention at least 6-foot care instruction to be given for Ato Kebede.

2.1.2.3 Medical laboratory technologists

Instructions: choose the appropriate answer from the alternatives given for each question and write the answers on a separate sheet of paper.

1. Why is there a discrepancy between the whole blood glucose concentration and the plasma glucose concentration?
   A. Because there is a different distribution of Glucose in whole blood and plasma
   B. Because there is a high amount of water in plasma
   C. Because the cellular component in whole blood use glucose frequently
   D. None

2. One of the following methods of Glucose determination does use enzymatic reaction
   A. Folin- MU copper Reduction method
   B. Alkaline ferric cyanide method
   C. Hexokinase n.v. method
   D. Somogyi-Nelson method
3. Which of the following method is highly specific for glucose determination
   A. Alkaline ferric cyanide method  
   B. Copper Reduction method  
   C. Glucose oxidase method  
   D. O-Toluidine method

4. When does glucose appear in the wine
   A. When the urine glucose level higher than blood glucose level  
   B. When blood glucose level is between 60-110mg/dl  
   C. When the blood glucose level is greater than 180-200 mg/dl  
   D. When a person is started

5. One of the following methods for urinary glucose determination is highly specific
   A. Copper reduction method  
   B. O-Toluidine method  
   C. Reagent strip Tests  
   D. A and B

6. Sodium fluoride additive used in a specimen collected for Glucose
   A. Inhibits glycolytic enzymes from destroying the glucose  
   B. Precipitates the protein present  
   C. Prevents non glucose reducing substances from interfering with the testing  
   D. None of the above

7. In a person with normal glucose metabolism, the blood glucose level usually increases rapidly after carbohydrates are ingested, but returns to a normal level after
   A. 30 minute  
   B. 60 minute  
   C. 90 minute  
   D. 15 minute

8. Which of the following organs uses glucose from digested carbohydrates and stores it as glycogen for later use as a source of immediate energy by the muscles?
A. Kidneys
B. Liver
C. Pancreas
D. Thyroid

9. Which of the following samples good for Glucose determination
   A. Serum/plasma
   B. Whole blood
   C. Urine
   D. All

10. To say the oral Glucose Tolerance test normal
    A. The fasting blood sugar level should be 60-110mg/dl
    B. The fasting blood sugar level should be higher than 110mg/dl
    C. The fasting blood sugar level should be normal or slightly elevated
    D. The fasting blood sugar level should be always less than the lower limit.

2.1.2.4 Environmental health officers
1. What situation makes difficult the study of causation of environmental factors and to link conclusively with DM?
2. Why diabetes mellitus patients are most susceptible for different kinds of skin infections?
3. What is the basic reason for the fact that E.H.Os are supposed to be highly concerned to make the working places free of any possible causalities for DM patients?
4. What are the known environmental factors that are thought to cause DM?
5. What parcel of Health information is highly beneficial for the family or community with strong DM history?
2.2 Significance and Brief Description of Diabetes Mellitus

Diabetes mellitus is a chronic illness that affects more than 170 million people worldwide. It is an important cause of morbidity and mortality.

It is

- Responsible for many cases of ESRD
- An important cause of blindness
- A leading cause of non-traumatic lower limb amputations
- Closely related with cardiovascular disease which is
  - A major cause of diabetes related deaths
  - 2-4 times more common in patients with diabetes mellitus than in the general population
- Associated with an increased risk of cerebrovascular accidents
- Associated with reduced life expectancy by as much as 5-10 years in middle aged patients

2.3 Learning Objectives

- After reading the module, one will be able to
- Explain the importance of diabetes mellitus as a public health problem
- Describe diabetes mellitus, its classification and clinical presentation.
- Outline the diagnostic tests for diabetes mellitus.
- Describe the logic behind appropriately employed treatment.
- Describe the role played by each member of the health center team.
- Describe the overall principles of management.

2.4 Learning Activity

2.4.1 Case Study

Wogemo Olijura is a 16-year-old boy, who presented to Leku health center on 20/11/2002 with complaints of excessive thirst, frequent urination, nausea, vomiting
abdominal pain, easy fatigability and blurred vision of one-week duration. His condition slowly deteriorated in the period of time that he has been ill and he was drowsy. The health officer on duty examined him and the findings were an acutely sick looking boy who was conscious and in respiratory distress. He also noticed a fruity odor on the boy's breath. He had a right radial pulse rate of 126 per minute, which was feeble. Blood pressure was 80/50 with the measurement taken in the supine position from the right arm. Respiratory rate was 32 per minute and it was deep. His eyes were sunken and his tongue was dry.

The health officer ordered the following investigations with the results shown.

RBS = 450mg/dl
WBC = 17,500 with 78% of the cells being PMNs
Urine analysis revealed glycosuria of 4+ and ketonuria of 4+.

On further questioning it was found out that he lives in a one room thatched roofed house with his seven siblings and parents. There is no window in the house; the cattle are kept in the same room and firewood is burned in the same room. The house is very badly lit with the only source of light being the daylight coming through the door. He comes from a rural village 15Km far from the health center and had to be carried all the way to the health center by his relatives. There is no history of diabetes mellitus in the family.

Questions related to the case study

1. What are the diagnostic possibilities?
2. Did the health officer request appropriate investigations?
3. What is the first step to be taken in managing the above patient?
4. What management difficulties do you anticipate in managing this patient?
DEFINITION
Diabetes Mellitus is a clinical syndrome comprising a heterogeneous group of metabolic diseases that are characterized by chronic hyperglycemia and disturbances in carbohydrate, fat and protein metabolism secondary to defects in insulin secretion, insulin action or both.

CLASSIFICATION OF DIABETES MELLITUS
Based on the pathologic process considered to be responsible for hyperglycemia, diabetes mellitus can be classified into

- **Type 1 Diabetes Mellitus**
  - Autoimmune destruction of the pancreatic islet β-cells with absolute loss of insulin secretion
  - In few patients the pathogenesis remains idiopathic

- **Type 2 Diabetes Mellitus**
  - is a heterogeneous group of disorders usually characterized by variable degrees of insulin resistance, impaired insulin secretion, β-cell dysfunction and dysregulated hepatic glucose production

- **Other specific subtypes of Diabetes Mellitus**
  - Genetic defects of β-cell function
  - Genetic defects of insulin action
  - Diseases of the exocrine pancreas
  - when the majority of pancreatic islets (>80%) are destroyed as in
    - pancreatitis
    - pancreatectomy
Endocrinopathies
  - acromegaly
  - Cushing’s disease
  - Pheochromocytoma
  - Glucagonoma
  - Etc

Drug or chemical induced
Infection
  - Congenital rubella
  - Cytomegalovirus
  - Etc

- **Gestational Diabetes Mellitus**
  Is glucose intolerance that develops and first becomes recognized during pregnancy and resolves following delivery.
  - Insulin resistance related to the metabolic changes of late pregnancy increases insulin requirements and may lead to hyperglycemia or impaired glucose tolerance.

NB The terms insulin-dependent diabetes mellitus (IDDM) and noninsulin-dependent diabetes mellitus (NIDDM) are obsolete.

**Epidemiology**
The prevalence of diabetes mellitus has risen dramatically in the past two decades; it is also projected that the number of individuals with diabetes mellitus will continue to increase in the near future.
The prevalence of diabetes mellitus is reaching epidemic proportions, in large part because of obesity and sedentary life style in both adults and children.
The incidence and prevalence of diabetes mellitus in the general Ethiopian population are unknown. A population based study done near Gondar on 2381 individuals using glycosuria screening with blood glucose confirmation showed glucose intolerance in...
only 0.5%. 86% of the study subjects were under 20 years of age, however, and the figure for those above 40 was found to be 2.4%.

**CLINICAL FEATURES**

Classical symptoms

- Thirst
- Polyuria
- Nocturia
- Rapid weight loss
- Increased susceptibility to infection in patients with uncontrolled diabetes
- Chronic fatigue and malaise

Signs

- Signs related to acute and chronic complications

**General Comparison of type 1 and type 2 diabetes mellitus**

<table>
<thead>
<tr>
<th></th>
<th>Type 1</th>
<th>Type 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous terminology</td>
<td>IDDM</td>
<td>NIDDM</td>
</tr>
<tr>
<td>Relative frequency</td>
<td>5-10% of the diabetic population</td>
<td>90-95% of the diabetic population</td>
</tr>
<tr>
<td>Age at onset</td>
<td>&lt;30 years</td>
<td>Usually &gt;40 years</td>
</tr>
<tr>
<td>Precipitating and associated risk factors</td>
<td>Largely unknown; microbial, chemical, dietary etc</td>
<td>Age, obesity, sedentary lifestyle, previous gestational diabetes</td>
</tr>
<tr>
<td>Endogenous insulin reserve</td>
<td>Low or absent</td>
<td>Usually present</td>
</tr>
<tr>
<td>Stress, withdrawal of insulin</td>
<td>Ketoacidosis</td>
<td>Nonketotic hyperosmolar state</td>
</tr>
<tr>
<td>Human leukocyte antigen association</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Family history of Diabetes mellitus</td>
<td>Infrequent</td>
<td>Frequent</td>
</tr>
</tbody>
</table>
DIAGNOSIS
Criteria for the Diagnosis of Diabetes Mellitus
Symptoms of diabetes plus random blood glucose concentration >200 mg/dL
Or
Fasting plasma glucose > 126 mg/dL
Or
Two-hour plasma glucose > 200 mg/dL during an oral glucose tolerance test

In the absence of unequivocal hyperglycemia and acute metabolic decompensation, these criteria should be confirmed by repeat testing on a different day.

COMPLICATIONS OF DIABETES MELLITUS
- May be classified into acute and chronic complications
- Acute complications are
  - Diabetic ketoacidosis
  - Nonketotic hyperosmolar state
  - Hypoglycemia
- Chronic complications
  - Affect many organ systems
  - Are responsible for the majority of morbidity and mortality associated with the disease
  - Can be subdivided into vascular and non-vascular complications
    - This division is rather arbitrary since it is likely that multiple pathogenic processes are involved in all forms of complications.
      - The vascular complications are further subdivided into
        - Microvascular complications that includes
          - Diabetic retinopathy
          - Diabetic nephropathy
          - Diabetic neuropathy
        - Macrovascular complications
        - Coronary artery disease
• Peripheral vascular disease
• Cerebrovascular disease
  • The non-vascular complications are
• Gastroparesis
• Sexual dysfunction
• Skin changes

Laboratory Evaluation
Aims
• To determine degree of metabolic control
• Define associated complications
Extent of tests shall be individualized.

Tests to be Carried Out
• Generally included are
• Fasting blood glucose (FBS)
• Random blood sugar (RBS)
• HbA1c
• Urinalysis
  • Ketones
  • Glycosuria
  • Protein
Serum lipid profile
Serum BUN and creatinine
Baseline electrocardiography
MANAGEMENT

OVERALL PRINCIPLES

The goals of therapy for patients with type 1 or type 2 diabetes mellitus are to:

- eliminate symptoms related to hyperglycemia,
- reduce or eliminate the long-term microvascular and macrovascular complications of diabetes mellitus and
- allow the patient to achieve as normal a life-style as possible

The care of an individual with either type 1 or type 2 diabetes mellitus requires a multidisciplinary team.

Patient education, dietary management and exercise play a central role in managing diabetic patients in addition to pharmacologic therapy.

Patient Education

- It should be viewed as a continuing process with regular visits for reinforcement and not just a one-time affair.
- Involves education of the patient and family members about a number of issues important for optimal diabetes care, including
  - self-monitoring of blood glucose
  - urine ketone monitoring (for those with type 1 diabetes mellitus)
  - insulin administration, if necessary
  - guidelines for diabetes management during illnesses
  - management of hypoglycemia
  - foot and skin care
  - diabetes management before, during, and after exercise
  - risk factor-modifying activities
Dietary Management
This involves optimal coordination of caloric intake with other aspects of diabetes therapy like insulin, exercise and weight loss

Aims of Dietary Management

- Abolish symptoms of hyperglycemia
- Avoid hypoglycemia associated with therapeutic agents (insulin, oral glucose lowering agents)
- Reduce overall blood glucose and minimize fluctuations
- Avoid atherogenic diets or those which may aggravate diabetic complications (e.g. high protein intake in nephropathy)
- For a patient with type 1 diabetes mellitus the aim of dietary management is to coordinate and match the caloric intake, both temporally and quantitatively, with the appropriate amount of insulin.
- In type 2 patients, it should address the greatly increased prevalence of cardiovascular risk factors (hypertension, dyslipidemia, obesity) and disease in this population. The majority of these individuals are obese, and weight loss is strongly encouraged and should remain an important goal
- Food intake must be spread evenly throughout the waking hours and taken at regular times in relation to the insulin dose.
- Patients should be advised to spread whatever food is available through the day and the reasons explained.
- The diet should be balanced in relation to its composition of fats (<30%), protein (10-20%), and carbohydrates (50-60%).
- Simple sugars that are rapidly absorbed should be avoided.
- Soluble fiber in the diet that delays the absorption and dampens postprandial hyperglycemia should be taken.
General Dietary Instructions

Food items the diabetic should avoid (rapidly absorbed carbohydrates)

Sugar, honey, jams, candy, marmalade
Cakes, Sweet Biscuits
Soft drinks (Coca Cola, Mirinda etc.)
Alcohols

Foods which the diabetic can take with restrictions

Food items from grains: enjera, bread, kinche, kita, atmit
Foods items prepared from peas, beans, lentils, chick peas
Potato, sweet potato, kocho, bulla

Food items the diabetic can take freely or with minimal restrictions

Lean meat and fish
Eggs, milk, cottage cheese
Green leafy vegetables (cabbage, tomato, pumpkin, carrots, onion)
Tea, coffee and lemon juice without sugar, Ambo water, other mineral waters
Spices: pepper, garlic, ‘berbere’

Exercise

It has multiple positive benefits (cardiovascular benefits, reduced blood pressure, maintenance of muscle mass, reduction in body fat, weight loss, etc.). Despite its benefits, exercise presents several challenges for individuals with diabetes mellitus because they lack the normal glucoregulatory mechanisms.

Individuals with type 1 DM are prone to either hyperglycemia or hypoglycemia during exercise, depending on the pre-exercise plasma glucose, the circulating insulin level, and the level of exercise-induced catecholamines.

If the insulin level is too low, the rise in catecholamines may increase the plasma glucose excessively, promote ketone body formation, and possibly lead to ketoacidosis.
If the circulating insulin level is excessive, this relative hyperinsulinemia may reduce hepatic glucose production (decreased glycogenolysis, decreased gluconeogenesis) and increase glucose entry into muscle, leading to hypoglycemia.

To avoid exercise-related hyper- or hypoglycemia, individuals with type 1 diabetes should

- monitor blood glucose before, during, and after exercise
- delay exercise if blood glucose is > 250 mg/dL, <100 mg/dL, or if ketones are present
- eat a meal 1 to 3 hours before exercise and take supplemental carbohydrate feedings at least every 30 min during vigorous or prolonged exercise
- decrease insulin doses (based on previous experience) before exercise and inject insulin into a nonexercising area.

In individuals with type 2 DM, exercise-related hypoglycemia is less common but can occur in individuals taking either insulin or sulfonylureas.

**MANAGEMENT OF THE TYPE 1 DIABETIC PATIENT**

**Insulin Therapy in Type 1 Diabetes Mellitus**

Type 1 diabetic patients have an absolute requirement for insulin. In general, they require 0.5-1.0 U/Kg per day of Insulin. Insulin formulations are available as U-100 (1ml of solution equivalent to 100 units) or U-40 (1ml of solution equivalent to 40 units).

It is very important that one designs and implements an insulin regimen that mimics physiologic insulin secretions. Twice daily administration of a short acting and intermediate acting insulin, given in combination before breakfast and the evening meal, is the simplest and most commonly used regimen.

Two thirds of the dose is given in the morning and one third is given in the evening.

Side effects of insulin therapy

- Hypoglycemia
- Weight gain
- Peripheral edema (in the short term)
Insulin antibodies
Local allergy
Lipodystrophy at insulin injection sites

Insulin Preparations
Main types of therapeutic insulin

<table>
<thead>
<tr>
<th>Species</th>
<th>Bovine</th>
<th>Porcine</th>
<th>Human</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purity</td>
<td>Conventional</td>
<td>Single peak</td>
<td>Highly purified</td>
</tr>
<tr>
<td>Duration of action</td>
<td>Short</td>
<td>Intermediate</td>
<td>Long</td>
</tr>
</tbody>
</table>

MANAGEMENT OF THE TYPE 2 DIABETIC PATIENT

Goals of Therapy

- Improved glycemic control
- Treatment of conditions associated with type 2 diabetes mellitus
  - Obesity
  - Hypertension
  - Dyslipidemia
  - Cardiovascular disease
- Detection and management of diabetes mellitus related complications

In a newly diagnosed type 2 diabetic, one should resort first to dietary management and exercise before embarking on pharmacologic measures. Glycemic control is reassessed and if response is not achieved, pharmacologic agents may be tried.
Oral glucose lowering agents are preferred as the initial choices to lower serum glucose levels.

As type 2 diabetes is a progressive illness, monotherapy is seldom successful in the long term.

Therapy is initiated with one class of agent, depending on patient characteristics and a second agent is added if adequate glycemic control is not achieved.

**Groups of Oral Antidiabetic Agents with Examples**

- **Sulphonylureas**
  - Glibenclamide

- **Biguanides**
  - Metformin

- **Alpha-glucosidase inhibitors**
  - Acarbose

- **Thiazolidinediones**
  - Troglitazone

**PREVENTION AND CONTROL**

**Screening**

Many patients with diabetes mellitus are unaware that they have diabetes mellitus and type 2 diabetes mellitus may be present for up to a decade before diagnosis.

Many patients with type 2 diabetes mellitus have one or more of diabetes mellitus related complications at diagnosis.

For the above reasons, it is recommended to screen those at risk of developing diabetes mellitus using fasting blood glucose.

This includes:

- Those above 45 years of age every three years
- Those with family history of diabetes mellitus (parent or sibling with type 2 diabetes mellitus)
- Obesity as evidenced by BMI > 27Kg/m²
• History of delivering a baby weighing above 4Kg or previous episode of gestational diabetes mellitus
• Hypertension

A number of lifestyle modification and pharmacologic agents are suggested to prevent or delay its onset.

High risk individuals should be encouraged to
• Maintain a normal body mass index
• Engage in regular physical exercise

The morbidity and mortality of diabetes mellitus related complications can be greatly reduced if detected and treated at an early stage. These screening procedures are indicated for all patients with diabetes mellitus.

Included under these procedures are
• Self monitoring of blood glucose
• HbA1c testing (2-4 times/ year)
• Annual patient education
• Screening for hypertension and dislipidemia
• Annual comprehensive eye examination by a qualified ophthalmologist
• Annual foot examination

COMPLICATIONS OF DIABETES MELLITUS

DIABETIC KETOACIDOSIS (DKA)

DKA is a major cause of medical emergency and a serious cause of morbidity.

It is most commonly seen in patients with type 1 diabetes mellitus, but it can also be seen in type 2 diabetics especially during acute illness.

Clinical Features
Symptoms
• Nausea/vomiting
• Thirst/Polyuria
• Abdominal pain
• Shortness of breath
• Blurred vision
• Weight loss
• Altered mental state

Physical findings

• Tachycardia
• Hypotension
• Tachypnea/ respiratory distress
• Kussmaul’s respiration (deep, fast breathing)
• Fever/hypothermia
• Dry mucous membranes/reduced skin turgor
• Abdominal tenderness
• Lethargy/obtundation/ possibly coma

Signs of infection, which may precipitate DKA, should be sought on physical examination, even in the absence of fever.

Abdominal pain may be severe and sometimes may be mistaken for an acute abdominal condition like pancreatitis or ruptured viscous.

Pathophysiology

DKA results from insulin deficiency combined with counterregulatory hormone excess (glucagon, catecholamines, cortisol, and growth hormone). Both insulin deficiency and glucagon excess, in particular, are necessary for DKA to develop.

The hyperglycemia of DKA results from
• increased hepatic glucose production via
  • gluconeogenesis
  • glycogenolysis
• Impaired peripheral glucose utilization

Ketosis results from a marked increase in free fatty acid release from adipocytes, with a resulting shift toward ketone body synthesis in the liver. Reduced insulin levels, in combination with elevations in catecholamines and growth hormone, lead to an increase in lipolysis and release of free fatty acids. Normally, these free fatty acids are converted to triglycerides or very low density lipoproteins (VLDL) in the liver, but in DKA, hyperglucagonemia alters hepatic metabolism to favor ketone body formation.

Average losses of Fluid and Electrolyte in DKA of moderate severity
• Water: 6 Liters
• Sodium: 500 mmol
• Chloride: 400 mmol
• Potassium: 350 mmol

Precipitating Events
• Inadequate insulin administration
• Infection (pneumonia, UTI, gastroenteritis, sepsis)
• Infarction (cerebral, coronary, mesenteric, peripheral)
• New onset diabetes
• Drugs

Laboratory Abnormalities and Diagnosis

DKA is characterized by
• Hyperglycemia RBS>250mg/dL,
• Ketosis
  • Ketone bodies positive at serum dilution of ≥1:2
  • Ketonuria of 2+ or above
• Metabolic acidosis (increased anion gap)
  • $P^H$ of 7.3 or lower and a bicarbonate level of ≤15 mEq/L

Despite a total-body potassium deficit, the serum potassium at presentation is typically at the high end of the normal range or mildly elevated secondary to the acidosis.
TREATMENT

- Rehydration
- Insulin
- Treatment of the precipitating cause when applicable
- Management of acid base disturbance
- Management of electrolyte imbalance
- Supportive care
- Resumption of subcutaneous insulin therapy once patient is out of the state of DKA
- Patient education

With appropriate therapy, the mortality of DKA is low (<5%).
Mortality is related more to the underlying or precipitating event, such as infection or myocardial infarction.

Complications of DKA

- The major non-metabolic complication of DKA therapy is cerebral edema, which most often develops in children as DKA is resolving.
  - Over replacement of free water should be avoided.
- Venous thrombosis and adult respiratory distress syndrome occasionally complicate DKA.
- Disseminated intravascular coagulation (rare)
- Acute circulatory failure

NON-KETOTIC HYPEROSMOLAR COMA

It is the second major clinical presentation of uncontrolled diabetes mellitus.
It is almost exclusively seen in patients older than 60.
Precipitating factors include
- Drugs like beta-blockers
- Parenteral and enteral feeding
- Excessive intravenous glucose administration

As with DKA, osmotic diuresis is central to the pathogenesis but this develops more slowly.
Dehydration is made worse by limited access to water and by the reduced perception of thirst in the elderly. Non-ketotic heperosmolar coma is characterized by marked hyperglycemia and loss of water up to 25% of body weight in severe cases.

### Differences between DKA and Non-Ketotic Hyperosmolar Coma (HONK)

<table>
<thead>
<tr>
<th></th>
<th>DKA</th>
<th>HONK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Any age</td>
<td>&gt;60</td>
</tr>
<tr>
<td>Presentation</td>
<td>Hours to days</td>
<td>Days or weeks</td>
</tr>
<tr>
<td>Mortality</td>
<td>5% overall</td>
<td>50%</td>
</tr>
<tr>
<td>Serum glucose</td>
<td>High</td>
<td>Very high</td>
</tr>
<tr>
<td>Serum osmolality</td>
<td>High</td>
<td>Very high</td>
</tr>
<tr>
<td>Serum sodium</td>
<td>Normal or low</td>
<td>Normal or high</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>Low</td>
<td>Normal or slightly low</td>
</tr>
<tr>
<td>Ketonuria</td>
<td>Present</td>
<td>Absent</td>
</tr>
</tbody>
</table>

The principles of treatment of HONK are similar to those for DKA. Rehydration is the most important initial treatment and isotonic saline is the fluid of choice. Less insulin is needed as compared to DKA early in treatment because acidosis is not a feature and rehydration alone lowers blood glucose.

**HYPOGLYCEMIA**

Hypoglycemia is defined as a recorded blood glucose concentration less than normal.

- Sometimes defined as a plasma glucose level <45 to 50 mg/dl
- The glucose thresholds for hypoglycemia-induced symptoms and physiologic responses vary widely, depending on the clinical setting.
- Clinically significant hypoglycemia is based on the demonstration of Whipple's triad that includes
  - symptoms consistent with hypoglycemia
  - a low plasma glucose concentration(<45mg/dL)
  - relief of symptoms after the plasma glucose level is raised
CAUSES
Most commonly occurs as a side effect of the treatment of diabetes mellitus. Incidence increases with attempts to achieve euglyemia with tight control of glucose concentrations.

Other causes in patients with diabetes include:
- Overdose of insulin or oral agents
- Ill timed administration of insulin or oral agents
- Administration of the wrong type of insulin
- Missed or delayed meals or snacks
- Uncompensated exercise
- Alcohol consumption
- Concomitant chronic renal failure
  - Insulin clearance is reduced in patients with chronic renal failure

Hypoglycemia can cause significant morbidity and can be lethal, if severe or prolonged. It should be considered in any patient who presents with confusion, altered level of consciousness, or seizures.

The central nervous system cannot synthesize glucose or store enough glycogen for more than a few minutes' glucose supply.

The brain cannot use free fatty acids as an energy source, and ketone bodies, which are generated late, are not useful in acute hypoglycemia. Significant hypoglycemia, therefore, can cause both acute and chronic brain dysfunction.

**Morbidity related to severe hypoglycemia in diabetic patients**

CNS
- Coma
- Convulsions
- Brain damage
- Impaired cognitive function, intellectual decline
- Vascular events: TIA, stroke
Heart
  Cardiac arrhythmias
  Myocardial ischemia

Eye
  • Vitreous hemorrhage
  • ? worsening of retinopathy

Others
  • Hypothermia
  • Accidents

CLINICAL MANIFESTATIONS
The various signs and symptoms of hypoglycemia appear at different glycemic thresholds, related to different mechanisms. They are subdivided into autonomic and neuroglycopenic manifestations.

The autonomic signs and symptoms occur with a relatively milder degree of hypoglycemia. With worsening of the hypoglycemia, and consequent CNS glucose deprivation, the neuroglycopenic symptoms and signs set in.

Autonomic signs and symptoms
Result from increased autonomic nervous system activity

They include
  • Palpitations
  • Tremor or shaking
  • Nervousness, Anxiety
  • Irritability
  • Sweating
  • Hunger
  • Nausea, vomiting
  • Tingling, Paresthesias
  • Tachycardia
  • Hypertension
Adrenergic symptoms are mediated by norepinephrine released from sympathetic postganglionic neurons and the release of epinephrine from the adrenal medullae. Increased sweating is mediated by cholinergic sympathetic nerve fibers.

**Neuroglycopenic signs and symptoms**

Neuroglycopenic symptoms are the direct result of central nervous system neuronal glucose deprivation. Signs and symptoms include

- Confusion
- Odd behavior
- Inability to concentrate
- Drowsiness
- Visual disturbance
- Tingling around the mouth
- Convulsions
- Focal neurologic deficits e.g. hemiplegia
- Coma

**TREATMENT**

Urgent treatment is necessary in patients with suspected hypoglycemia. Blood should be drawn, whenever possible, before the administration of glucose to allow documentation of the plasma glucose level. Oral treatment with glucose tablets or glucose-containing fluids, candy, or food is appropriate if the patient is able and willing to take these. A reasonable initial dose is 20 g of glucose. If neuroglycopenia precludes oral feedings, parenteral therapy is necessary. Intravenous glucose (25 g) should be given using a 50% solution followed by a constant infusion of 5 or 10% dextrose. If intravenous therapy is not practical, subcutaneous or intramuscular glucagon can be used, particularly in people with type 1 diabetes mellitus. Because it acts primarily by stimulating glycogenolysis, glucagon is ineffective in glycogen-depleted individuals (e.g., those with alcohol-induced hypoglycemia). These treatments raise plasma glucose concentrations only transiently,
and patients should be encouraged to eat as soon as they are alert in order to prevent a recurrence.

**CHRONIC COMPLICATIONS OF DIABETES MELLITUS**

The microvascular complications of both type 1 and type 2 DM result from chronic hyperglycemia. It is also suspected that a genetic susceptibility for developing particular complications exists.

Evidence implicating a causative role for chronic hyperglycemia in the development of macrovascular complications is less conclusive.

Dyslipidemia and hypertension also play important roles in macrovascular complications.

Three major theories have been proposed to explain how hyperglycemia might lead to the chronic complications of diabetes mellitus. These are:

- formation of advanced glycosylation end products (AGEs) via the nonenzymatic glycosylation of cellular protein
- increased glucose metabolism via the sorbitol pathway
- increased formation of diacylglycerol leading to activation of certain isoforms of protein kinase C (PKC), which, in turn, affect a variety of cellular events that lead to diabetes mellitus-related complications

Studies have provided definitive proof that reduction in chronic hyperglycemia can prevent many of the early complications of type 1 DM.

The development of chronic complications correlates with the duration of diabetes and glycemic control.

**Ophthalmologic Complications of Diabetes Mellitus**

Diabetes mellitus is a leading cause of blindness in the working population in the developed world.

Blindness is primarily the result of progressive diabetic retinopathy and clinically significant macular edema.

Diabetic retinopathy is classified into two stages. These are non-proliferative and proliferative retinopathy.
Proliferative retinopathy
- retinal vascular micaroaneurysms
- blot hemorrhages
- cotton wool spots

Non-proliferative retinopathy
- Neovascularization is the hallmark.

The most effective treatment for diabetic retinopathy is prevention.
Intensive glycemic control will delay the development or slow the progression of diabetic retinopathy.
There may be a transient, paradoxical worsening of established diabetic retinopathy, during the first 6 to 12 months of improved glycemic control.
Regular, comprehensive eye examinations for all individuals with diabetes mellitus are required, and these should be performed by an experienced ophthalmologist.

Other Ocular Problems
- Cataract
  Develop early and progress rapidly in diabetic subjects
- Glaucoma
- Ocular palsies
- Sudden visual loss

Renal Complications of Diabetes Mellitus

Diabetic Nephropathy
- One of the commonest causes of end stage renal failure

Nephropathy progresses through the following stages:
- Hyperfiltration
  - Associated with increased glomerular size and kidney volume
  - Increased glomerular filtration rate
• Microalbuminuria
  • defined as excretion in a 24-h period of 30 to 300 mg/d of albumin (incipient nephropathy)
• Established nephropathy
  • Overt proteinuria (Urinary protein >300 mg/d)
  • Dipstick positive
• End stage renal disease
  • Renal failure that requires dialysis or transplantation

The optimal therapy for diabetic nephropathy is prevention. Interventions effective in slowing progression from microalbuminuria to overt nephropathy include near normalization of glycemia, strict blood pressure control and administration of ACE inhibitors.

**Diabetic Neuropathy**
Manifests as polyneuropathy, mononeuropathy, and/or autonomic neuropathy. The most common form of diabetic neuropathy is distal symmetric polyneuropathy often described as having a glove and stocking distribution. Most frequently presents with distal sensory loss. Hyperesthesia, parathesia, and pain also occur. Physical examination reveals sensory loss, loss of ankle reflexes, and abnormal position sense.

**Diabetic polyradiculopathy** is a syndrome characterized by severe disabling pain in the distribution of one or more nerve roots. It may be accompanied by motor weakness. **Mononeuropathy** presents with pain and motor weakness in the distribution of a single nerve. Involvement of the third cranial nerve is most common and is heralded by diplopia. Physical examination reveals ptosis and ophthalmoplegia with normal papillary constriction to light. Sometimes cranial nerves IV, VI, or VII (Bell's palsy) are affected. Peripheral mononeuropathies or simultaneous involvement of more than one nerve (mononeuropathy multiplex) may also occur.

**Autonomic Neuropathy** in diabetes can involve multiple systems, including: the cardiovascular, gastrointestinal, genitourinary, sudomotor, and metabolic systems. Autonomic neuropathies affecting the cardiovascular system cause a resting
tachycardia and orthostatic hypotension. Gastroparesis and bladder-emptying abnormalities are also likely related to the autonomic neuropathy seen in DM (discussed below). Hyperhidrosis of the upper extremities and anhidrosis of the lower extremities result from sympathetic nervous system dysfunction. Anhidrosis of the feet can promote dry skin with cracking, which increases the risk of skin ulceration. Autonomic neuropathy may reduce counterregulatory hormone release, leading to an inability to sense hypoglycemia appropriately (hypoglycemia unawareness, thereby subjecting the patient to the risk of severe hypoglycemia and complicating efforts to improve glycemic control.

One should consider other possible causes of neuropathy before ascribing signs and symptoms to be due to diabetic neuropathy as other causes of neuropathy may present in a similar manner.

**Diabetic foot disease**

Different types of diabetic tissue damage interact and combine in the feet, giving a wide variety of lesions ranging from relatively harmless dysesthesiae to fulminating infections and widespread ulceration and gangrene.

Factors that play important roles in the pathogenesis of diabetic foot ulcers include,

- Neuropathy  
  o Predisposes patient to repetitive trauma to the feet
- Reduction in blood flow  
  o Delays wound healing  
  o Serves as a good medium for bacterial multiplication
- Deformity in the feet  
  o This leads to abnormal foot mechanics with misdistribution of pressure over parts of the feet.
- Reduced anti-infective activity of leucocytes of hyperglycaemic patients
- Poor eye sight of diabetics
Preventive management is as important as correct treatment of established lesions. The main aim is to prevent excessive pressure on particular areas of skin.

- Look for corns and callosities on the soles or heels.

Patients should be advised to inspect their feet regularly.

If the diabetic cannot see his feet properly, someone else must look at them at least weekly or, if there is marked loss of pinprick sensation, thrice weekly.

The principles of treatment of diabetic foot ulcers involve the elimination of infection by draining pus or removing infected bone, by removing dead tissue likely to provide a focus for infection, and by using antibiotics if necessary.

Healing is speeded by encouraging the greatest possible blood flow, and protecting the foot from trauma.

Debridement must be thorough and extensive.

Amputation may be required in case of life threatening infections by gas forming organisms or in cases where there is of dead tissue.

Antibiotics choice should be guided by culture of either the local lesion or blood when infection is widespread.

The control of glucose levels should be as strict as possible, as hyperglycemia is bound to bring about dysfunction of the leucocytes.

**DIABETIC HEART DISEASE**

Several different processes contribute to diabetic heart disease. These include

- Abnormalities in plasma lipids
- Increased liability to hypertension in diabetics
- Structural narrowing of the lumina of vessels
- The presence of a state that favors coagulation

Patients may present with either clinical features of ischeamic heart disease or congestive heart failure in the absence of ischeamia (diabetic cardiomyopathy).
A greater proportion of cardiac infarcts seem painless in patients with diabetes than in non-diabetics. 
Heart disease is the major cause of death among both type 1 and type 2 diabetics, and ultimately is likely to affect about 60 per cent of patients.
The management of ischaemic heart disease among diabetics differs little from that generally employed.
Life style modification plays a big role in the management. Patients should be advised to stop smoking.
Diabetes Mellitus

I. Definition
A group of metabolic disorders characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both

II. Classification
1. Type 1 diabetes Mellitus
Previously called insulin dependent DM or Juvenile onset DM due to its usual onset in adolescence or childhood
It includes about 5-10% of all diabetic patients and is caused by autoimmune destruction of the B-cells of the pancreas. The resulting hyperglycemia is responsible for the acute and chronic complications of the disease.
In few patients with type 1 DM the pathogenesis remains idiopathic.

2. Type 2 DM
This class of diabetes also known as non-insulin dependent DM accounts for 90-95% of the population with DM. It is common in people older than 40yrs and results from variable combinations of insulin resistance and defects in insulin secretion.

Learning Activity
In the exercise in the core module,
1. Identify the key historical findings suggesting the diagnosis.
2. Identify the key physical findings supporting the diagnosis of type 1DM
3.    In the hypothetical case already mentioned the health officer requested the following laboratory investigations with the results shown below.

RBS = 450mg/dL
U/A - glucose = 4+
    - ketones =4+
    - Albumin =negative

3.1. Do the findings on laboratory investigation support (refute) your clinical suspicion?
3.2. What additional investigation would you request if resources permit?

III. Diagnosis

1. Clinical features
   The presentation of patients depends on the type of diabetes and the stage of pathologic process.

   1.1. Type 1 DM
   Patients with type 1 DM commonly present with the classic acute symptoms of hyperglycemia: excessive thirst (polydipsia), polyuria, polyphagia and weight loss. Twenty five percent of type 1 diabetics present for the first time with diabetic ketoacidosis (DKA) characterized by hyperglycemia, ketosis and acidosis.

   1.2. Type 2 DM
   The presentation of type 2 diabetes is less acute than type 1 with “poly” symptoms and accompanying lethargy and fatigue.

   The disease is often present for many years before the diagnosis and chronic hyperglycemia may be responsible for susceptibility to infections (eg. vaginitis)
2. Criteria for the Diagnosis of DM

DM can be diagnosed in the presence of any of the following

2.1. “Poly” symptoms plus casual plasma glucose greater than or equal to 200mg/dl
2.2. Fasting blood glucose (FBG) greater than or equal to 126 mg/dl
2.3 Two hours plasma glucose of greater than or equal to 200 mg/dl during an oral glucose tolerance test (OGTT).
   (OGTT – Plasma glucose measurement after 75g of anhydrous glucose load).

NB: In the absence of unequivocal hyperglycemia the criteria should be confirmed by repeat testing on a different day.

IV. Management

The goals of management are:

1. Short term – immediate treatment to relieve the symptoms such as polydipsia, polyuria, or acute infection.
2. Intermediate – to return the patient to physiologic state and social life.
3. Long term – to prevent the development or delay progression of complications of diabetes

The treatment of diabetes can be categorized as non-drug therapy and drug therapy.

1. Non – Drug Therapy
   1.1. Regular Physical exercise
   This results in improvements in the sense of well being, cardiovascular fitness, blood pressure, insulin sensitivity, weight reduction and glycemic control. Regular physical exercise for at least 30 minutes a day is recommended.

Blood glucose should ideally be measured before any exercise which shouldn’t be undertaken with FBS of 300 mg/dl and above on the other hand if FBS is less than 100mg/dl exercise may precipitate hypoglycemia and carbohydrate should be
consumed in advance medical evaluation is advised to determine the level of fitness and appropriate exercise based on the presence and degree of macrovascular and cardiovascular complications.

1.2. Dietary Control
A general dietary recommendation includes consumption of a balanced health diet composed of:

- 10 – 20% protein
- 30% fat
- 50-60% carbohydrate

Patients should be advised to avoid dimple sugars like table sugar, honey etc and low saturated fat and cholesterol white high fiber diet is recommended.

2. Drug Therapy
2.1. Type 1 DM
Patients with type 1 diabetes have an absolute requirement of insulin for survival. Insulin is also used in type 2 diabetics when a combination of oral agents fails to achieve glucose targets and temporarily in patients with serious infection or surgery. The types of insulin available are rapid acting, short acting, intermediate acting and long acting.

Standard insulin therapy consists of one to two injections per day using intermediate or long acting insulin with or without regular insulin. Starting insulin does vary from 0.15 to 0.50/kg (as high as 1.5 u/kg in cases of severe insulin resistance) depending on patient size and degree of glycemia.

Adults of normal weight may be started with 20-25 u/d of intermediate acting insulin and increased to maintain a blood sugar level of 80-120 mg/dl.
2.2. Type 2 DM

Provided pharmacologic therapy is not required immediately all patients should be given at least a one month trial of diet, exercise and weight management. If this regimen does not lead to adequate blood glucose control, oral antihyperglycemic agents with or without insulin are indicated. Insulin may be needed in symptomatic patients who have type 2 DM with FBG values greater than 250 mg/dl. The common antihyperglycemic agents in use are discussed below.

a. Glibenclamide

Dosage
- 2.5–20 mg daily or in two divided doses

Side effect
- hypoglycemia.

Contraindications
- hepatic and renal impairment.

Drug interactions
- alcohol – flushing

Dosage form
- tablets of 5 mg

b. Metformin

Dosage
- 500–2000 mg PO daily in divided doses

Side effects
- anorexia, nausea, vomiting, abdominal discomfort and diarrhea

Contraindications
- renal disease, hepatic disease, alcoholism

Dosage forms
- tablets of 500 mg.
V. Complications

The complications of DM can be divided into acute and chronic complications

1. Acute complications

1.1 Diabetic ketoacidosis (DKA)

It is a clinical condition that may be defined as a triad of

- Hyperglycemia
- Ketosis
- Acidosis

It usually occurs in the setting of type 1 DM and is primarily caused by relative or absolute insulin deficiency.

Common precipitating factors are infection and omission of insulin dose. Patients may also come with DKA on initial presentation.

Symptoms include nausea, vomiting, polydipsia, polyuria, abdominal pain and weakness. On examination, signs include tachycardia, orthostatic hypotension, poor skin turgor, warm or dry skin and mucous membranes, deep and fast breathing (Kussmaul’s respiration), hypothermia or normothermia, acetone breath, and altered mental status or coma.

Investigations:

- Blood glucose greater than 250 mg/dl
- Ketosis: ketonuria of 2+ to 3+

Treatment

- Non drug treatment: correct or treat the precipitating factor
- Drug treatment includes insulin, fluid replacement, and potassium replacement
  
  Insulin
  
  20U of regular insulin (10IM/10IV) followed by 5U IM every hour in adults (0.1U/kg/h in children)

  Blood glucose should be checked every two hours. If after the first two hours blood glucose level has not fallen significantly, dose of IM insulin can be doubled. When the patient is completely out of ketosis (evidenced by absent
urinary ketones) regular insulin is given 6 hours subcutaneously according to random blood sugar (RBS) level as follows:

- RBS > 250 mg/dL - 12 units
- RBS: 180-250 mg/dL - 8 units
- RBS – 120-180 mg/dL - 4 units
- RBS < 120 but > 70 mg/dL - 70 units; no insulin
- RBS < 70 mg/dL - Hold insulin and give juice or meal and recheck blood glucose in one hour.

**Fluid Replacement**

Normal saline IV should be given rapidly as soon as the patient arrives. Total fluid given may be as high as 10 litres depending on the patient’s response & urine output.

Fluid replacement may proceed in the following manner.

- 2-3L of 0.9% saline over first 1-3 hour (5-10mL/Kg per hour); subsequently, 0.45% saline at 150-300mL/hr; change to 5% glucose and 0.45% saline at 100-200mL/hr when plasma glucose reaches 250mg/dL.

**Electrolyte Replacement**

Potassium replacement should be according to serum potassium values. Potassium, 20 meg 1h is generally safe if renal function is normal

SE. renal failure

Dosage forms, injection 20 meg /10 ml ampoule of kc/
3.2 SATELLITE MODULE FOR BSC NURSES

Directions for using the module

Before starting to read this module, please follow the directions given below

- Go through all the contents of the Core Module by starting with the pre test
- Use a separate sheet of paper to write your answers and label it as pre-test answers

Learning objectives

On completion of this module, the learner will be able to

1. Differentiate between type 1 and type 2 diabetes
2. Describe etiologic factors associated with diabetics
3. Understand the function of glucose and insulin
4. Relate the clinical manifestation of diabetic mellitus to the associated pathophysiologic alteration
5. Recognize the seriousness of DM with reference to morbidity and mortality
6. Identify the diagnostic and clinical significance of blood glucose tests
7. Describe the various type of insulin
8. Explain the dietary modification used for management of person with diabetes
9. Describe the relationship between diet, exercises and modification for persons with diabetes
10. Develop a plan for teaching insulin self administration
11. Learn on the pharmacological calculation of insulin to reach on accurate dose (units to milliliter from a vial containing 40,80 or 100 units)
12. Differentiate between hypoglycemia and Diabetic ketoacidosis and HHNS
13. Describe the major macrovascular, microvascular and neuropathic complication of diabetic and self care behavior important in the prevention
14. Explain why the are of such importance
15. Use the Nursing process as a frame work for care of the patient with diabetes
Diabetes Mellitus

Definition: - is a chronic multifactorial, systemic metabolic disorder characterized by hyperglycemia and abnormal insulin production and/or action.

Insulin is a hormone produced by the pancreas. It controls the level of glucose in the blood by regulating the production and storage of glucose.

-Beta cells are responsible for production and secreting insulin and glucagon.

-It is anabolic or storage hormone
  - When a meal is eaten, insulin secretion increases and moves glucose from the blood into the muscle, liver, and fat cell.
  
  In those cells insulin has the following effect.
  
  - Stimulate storage of glucose in the liver and muscle
  - Enhance storage of dietary fat in the adipose tissue
  - Accelerate transport of amino acid into the cells

Also inhibit the break down of stored glucose, protein and fat

Glucagon-a relative or absolute excesses of glucagon are an essential factor in the development of DM. It increases blood glucose concentrations

Classification of diabetes

Type 1-IDDM
Type 2-NIDDM

Other specific subtype- like malnutrition related Diabetic Mellitus (MRDM), gestational DM

Characteristics of type 1 & type 2 DM (compare & contrast)

See the Core Module

Etiology

Type 1 DM
  - Is characterized by destruction of the pancreatic beta cells
  - The exact cause is unknown
- But it is thought that a combination of
  - Genetic susceptibility
  - Environmental factors that contribute to beta cell destruction and
  - Genes regulating immune response are involved

Type 2 DM
- Is related to insulin resistance (a decreased sensitivity to insulin) and impaired insulin secretion
- But the exact mechanism is unknown
- Risk factors include:
  → Age (insulin resistance tends to increase with age over 65)
  → Obesity
  → Family history is strongly associated or environmental factors, e.g. Viruses

Diagnostic Criteria for Diabetic Mellitus
Fasting plasma glucose (FPG) >126mg/dl
Random blood glucose (RBS) >200mg/dl with symptoms
2hr post load glucose >200mg/dl
See the Core Module for the details

Management
Goal: - to try to normalize insulin activity & blood glucose levels in an attempt to reduce the development of the vascular & Neuropathic complications.
There are five components of management for diabetes: -
  - Diet
  - Exercise
  - Monitoring blood glucose
  - Medication (as needed)
  - Education
I. Dietary Management

Goal: - provision of all the essential food constitutes (e.g., carbohydrate, proteins, fat, vitamins, minerals)
- Achievement and maintenance of reasonable weight
- Meeting energy needs
- Prevention of wide daily fluctuations in blood glucose levels with Blood glucose level as close to normal as is safe and practical
- Decrease blood lipid levels, if elevated

A. Calories

The most important objective in dietary management of DM is control the total calorie intake and to attain or maintain a reasonable body weight and control of blood glucose levels.

The general recommendation include consumption of a balanced healthy diet composed of the following

- 50% to 60% of calories to be derived from carbohydrates
- Less than 30% obtained from fat and
- The remaining 10% to 20% from protein

*Food which diabetic should avoid (rapidly absorbed carbohydrate/simple sugar)*

1) Sugar, honey, jam, marmalade and candy
2) Cakes and sweet biscuits
3) Soft drink (Fanta, coca cola, etc)
4) Alcohol (Cognac, tej, araki, whisky)

There are types of alcohols which are allowed in moderation, that is less sweat drinks i.e. light beer or dry wine (not more than 2 drinks for men, 1 drink for women/day). Alcoholic beverage equivalent to 12 oz beer, 5 oz wine and 1.5 oz spirit. It should be always taken with food.
Foods which diabetic should take with restriction (cereals or starch 50 - 60 %)
   a. Foods from grain e.g. injera, bread, kinche, dabo kolo, kita , atemit
   b. Foods prepared from peas, beans, lentils
   c. Potato, sweat potato, kocho, bulla
   d. All fruits except lemons and grape fruit
   e. Macaroni, pasta, rice

Foods, which diabetics can take freely or with minimal restriction (protein 10-20%)
   A) Lean meat and fish (with minimal restriction)
   B) Eggs and milk (with minimal restriction)
   C) Green leafy vegetables (kale, salad, cabbage
   D) Lemon, grape fruit
   E) Tea, coffee, lemon juice without sugar, ambo water, other mineral water and clear soup
   F) Spices pepper, berbere
   G) Tomato, pumpkin, carrot, Onion, chili pepper

II. Exercise
   - Is extremely important in the management of diabetes because of its effect on lowering blood glucose and reducing cardiovascular risk factors
     - Lowers blood glucose level by increasing the uptake of glucose by body muscles and by improving insulin utilization
   - Pre or post exercise snack may be required to prevent hypoglycemia after exercise
   - Patients should be taught to do regular, moderate exercise at the same time and in the same amount for at least 30 minutes each day. Exercise recommendations must be altered as necessary for patients with diabetic complications
   - Blood glucose level should be measured before any exercise activity is initiated.
- Exercise should not be initiated with fasting plasma glucose > 250 mg/dl or < 100 mg/dl (because it may precipitate diabetic ketoacidosis and hypoglycemia respectively)

-Patient is advised to:
  - Use proper footwear and if appropriate other Protective equipment
  - Avoid exercise in extreme heat or cold
  - Inspect feet daily after exercise
  - Avoid exercising during periods of poor metabolic control.

III. Monitoring of Glucose and Ketones
  - Blood glucose level should be assessed frequently by the patient or by having follow-up in the health unit
  - Urine and ketone checks are appropriate if blood glucose is greater or equal to 250 mg/dl

IV. Medications
  Insulin therapy
  - In type 1 diabetes, the body loses the ability to produce insulin, thus, exogenous insulin must be administered indefinitely. A standard insulin treatment consists of one or two injection/day, using intermediate or long acting insulin with or without regular insulin.
  - In type 2 diabetes, insulin may be necessary on a long term basis to control glucose levels if diet and oral agents have failed. In addition, some patients whose type 2 diabetes is usually controlled by diet alone or diet and an oral agent may require insulin temporarily during illness, infection, pregnancy, surgery or some other stressful events.

Insulin preparation
  A number of insulin preparation are available. They vary according to four main characteristics, that is
1) Concentration –U-40
   -U-80
   -U-100
   -U-500

2) Species (source)- Human source
   -Animal source (beef/pork)

3) Manufacturer –Lilly
   -Novo nordisk companies

4) Time course of action –Rapid acting(regular)
   -Intermediate acting (NPH and lente)
   -Long acting(ultra lente)
   -Mixed (e.g 70%NPH/30%Reg)

<table>
<thead>
<tr>
<th>Time course</th>
<th>Agent</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short acting</td>
<td>Regular (R)</td>
<td>½-1 hr</td>
<td>2-3 hr</td>
<td>4-6 hr</td>
<td>Usually administered 20-30 minutes before meal</td>
</tr>
<tr>
<td>Intermediate acting</td>
<td>NPH (Neutal protamine Hagedorn) Lent e(L)</td>
<td>3-4hr</td>
<td>4-12hr</td>
<td>16-20 hr</td>
<td>Usually taken after food</td>
</tr>
<tr>
<td>Long acting</td>
<td>Ultralente (“UL”)</td>
<td>6-8 hr</td>
<td>12-16 hr</td>
<td>20-30hr</td>
<td>Used primarily to control fasting glucose level</td>
</tr>
</tbody>
</table>
Patient education -about Insulin Injection

- Insulin injections are administered into the **subcutaneous** tissue

- Equipment: - Insulin
  - Short acting insulin is clear in appearance and long acting insulin are cloudy and white
  - The long acting must be mixed (gently inverted or rolled in the hands) before use
  - Before injection it should have room temperature, which may require rolling it in the hands or removing it from a refrigerator for a time before the injection. Actually there is no significant difference in the biologic activity between insulin put in the refrigerator and in the temperature (25-34oc). It would seem safe to conclude that unless insulin in Africa is stored for a long period at very high temperature, there is no potential problem (5).
  - If a frosted, adherent coating is present, some of the insulin is bound and should not be used

**Syringes**

- Should be matched with the insulin concentration
  - 1 ml syringes – hold 100 units
  - ½ ml syringes – hold 50 units
  - 3/10 ml syringes – hold 30 units

**Preparing the injection**

Mixing insulin: - when short and long acting insulin is to be mixed first withdraw the regular insulin (short acting)

**Administering the injection**

Allow alcohol to evaporate from the skin before injection or avoid use of alcohol for cleansing

- **Four main areas**
  - Abdomen
- Arms (posterior surface)
- Thighs (anterior surface)
- Hips

Absorption is greatest in abdomen and decreases progressively in the arm, thigh, and hips.

**Rotation**
- Rotation of injection site is required to prevent lipodystrophy, localized changes in fatty tissue,

The patient is instructed as:
1. Do not use a site > once every 4 to 6 weeks
2. Sites should be 1 to 1 ½ inches apart
3. Use all sites in one geographic area, then move to the next area
4. Document site use

**Side effects of insulin injections**
1. Local allergic reactions.
   - This appears in the form of redness, swelling, tenderness, and indurations or a 2 to 4 cm wheal may appear at the injection site 1to 2 hrs after injection
   - Usually occur during the beginning stage of therapy and disappear with continued use of insulin
   - Antihistamine will be given 1 hr before injection
   - If alcohol is used to clean the area the skin should be allowed to dry
   - A local reaction is usually not dangerous unless it becomes more extensive over time

2. Systemic allergic reaction-are rare
   - Can be life threatening
   - Local skin reaction that gradually spreads in to generalized urticaria which can include laryngeal edema with respiratory distress
Treatment involves: - desensitization, gradually increasing the amount of insulin under cautious observation.

3. Insulin lipodystrophy

- Refers to a localized disturbance of fat metabolism in the form of lipoatrophy (loss of subcutaneous fat and appears as slight dimpling or more serious pitting of subcutaneous fat) or lipohyperthrophy (is the development of fibro fatty masses at the injection site and is caused by the repeated use of injection site)
- If insulin is injected in to scarred areas the absorption may be delayed

Treatment: Patient should avoid injection on the areas and prevent by rotating injection sites.

3. Insulin Resistance

- Insulin requirements up to 1u/kg can be seen with obesity, stress, aging
- Modest insulin resistance-2-3u/kg wt-can be seen frequently with type 2
- Extreme insulin resistance (>3u/kg)-is rare and may be caused by a variety of autoimmune and genetic disorder

**Oral Anti diabetic agents**

Effective for type 2 DM patients who do not respond to diet and exercise alone and who are able to produce some insulin

**A. Glibenclamide**

Dosage: 2.5 – 20mg daily or in two divided doses
Side effect: hypoglycemia.
Contraindications: hepatic and renal impairment.
Drug interactions occur with alcohol leading to flushing
Dosage form: tablet 5mg
**B. Metformin**

Dosage, 500 – 2000 mg Po daily in divided doses
Side effects: anorexia, nausea, vomiting, abdominal discomfort and diarrhea.
Contra-indication: renal disease, hepatic disease alcoholism
Dosage form: tablet, 500mg and 850mg

**Fig1: Algorithm for the control of type 2(NIDDM)**

1. **New NIDDM**
2. **Diet and life style advice**
3. **Still symptomatic**
   - **Start oral agents**
     - **Obese- metformin**
     - **None obese-glibenclamide**
4. **Increase dose monthly, if necessary to maximum dose**
   - **Patient well and asymptomatic**
     - **Continue at PHC clinic**
   - **Still not controlled, give combin Metformin and glibenclamide**
5. **Again, increase dose to the top**
6. **Still not controlled refer to the Dr.**
A. Acute complications of diabetes

1. Hypoglycemia (Insulin Reactions)
   - Occurs when blood glucose level falls below 50 to 60 mg /dl (2.7 to 3.3 mmol/L )
   
   **Caused by:** Too much insulin or hypoglycemic agents
   
   - Too little food or
   - Excessive physical exercise or excessive alcohol
   - Occurs also if meals are delayed or snacks are omitted

Symptoms includes

Mild hypoglycemia
   - Sweating
   - Tremor
   - Tachycardia
   - Palpitation
   - Nervousness and
   - Hunger

Moderate hypoglycemia
   - Inability to concentrate
   - Headache
   - Light headedness
   - Confusion
   - Memory lapses
   - Numbness of the lips and tongue
   - Slurred speech
   - In coordination
   - Emotional changes
   - Irrational behavior
   - Double vision and drowsiness

Severe hypoglycemia
   - Seizures
   - Difficulty arousing from sleep or
   - Loss of consciousness
Treatment for Mild and moderate hypoglycemia

10 to 15 mg of a fast acting sugar orally

<table>
<thead>
<tr>
<th>2-3 tsp</th>
<th>4 to 6 tsp</th>
<th>2 to 4 tsp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hard candies</td>
<td>sugar,</td>
<td>honey,</td>
</tr>
</tbody>
</table>

Treatment for Severe hypoglycemia

The initial treatment of a confused, comatose patient is to infuse a bolus of 50 ml of 50% glucose; preferably after a blood sample for lab analysis has been obtained. This bolus is followed by the continuous infusion of 5 to 10 % of glucose at a rate sufficient to keep the plasma glucose level $> 100 \text{mg/dl}$

Patient education:
- Prevented by following a regular pattern for eating, administering insulin, and exercising
- Because unexpected hypoglycemia may occur all patients treated with insulin should wear an identification bracelet or tag indicating that they have diabetes and should keep sugar or candy in their pocket
- Patient and family members should be aware of signs of hypoglycemia

2. Diabetic Ketoacidosis (DKA)

DKA is caused by an absence or markedly inadequate amount of insulin. Patients with sever DKA can become severely dehydrated with the loss of electrolyte. Volume loss is highly variable as is Na$^+$ and K$^+$ decreasing. Paradoxically potassium appear elevated as a response to acidosis, though this is a temporary shift of potassium from intra to extra cellular space

Sign and symptoms:
- Anorexia, nausea, and vomiting & abdominal pain
- Acetone breathe
- Kussmaul respiration (very deep & and fast respiration)
- Lab.value : Blood glucose level 300 to 800 mg /dL

Causes:
- A reduced or missed dose of insulin, an illness or infection
Treatment of DKA includes

- Fluid replacement if kidney functions is normal and there is no concern for heart disease
  - 0.9% normal saline of a very high rate usually 0.5 to 1 lit/hr for 2 to 3 hrs, then the decrease the rate to 250-500ml/hr as orthostatic change disappear.
  - Fluid may need to be given cautiously in renal impaired or older patients who may have underlying new problems
  - Hypotonic normal saline (0.45%) for hypertensive
  - K- replacement – Give none with the first liters of saline, then 20 mmol hourly in saline up to a total of 80 mmol
  - Insulin IV at a slow, continuous rate (start with a 10u bolus of regular insulin IV, followed immediately by a continuous IV insulin infusion at 0.1u/kg/hr if weight is known, if not 6u/hr, when the patient starts to eat and drink change to subcutaneous 30 min before meal and discontinue insulin infusion 30-60 min after meal.
  - Hourly monitoring of blood glucose level, urine glucose level, blood ketone level Alter insulin if necessary accordingly
  - Bicarbonate infusion- doesn't give routinely. Give 50 mmol slow IV only if patients condition is critical.

3. Hyperglycemic Hyperosmolar Nonketotic syndrome (HHNK)
- is a situation in which hyperosmolarity and hyperglycemia predominate, with alteration of the sensorium (sense of awareness). See the core module for the details

Clinical manifestations

* Symptoms of hypotension
  - Profound dehydration
  - Tachycardia and
  - Neurologic signs (e.g. altered sensorium, seizures, hemiparesis)
Causes: - Occurs most frequently in older people (50-70 yrs) who had no previous history of DM or only mild type 2 diabetes and renal impairment

Precipitating events
- Acute illness
- Ingestion of medication known to provoke insulin insufficiency (thiazide diuretics, propranolol) or
- Therapeutic procedures

Management: . Similar with diabeticketoacidosis (DKA)

Fluid, electrolyte and insulin replacement
1) Water loss is usually more severe that electrolyte depletion give patient 1-2 litter 0.9% normal saline, if hypotensive followed by .45% normal saline.
2) Infusion rate should be based on renal and cardiac status
3) Insulin requirements are often low.

B. Long term Complications of diabetes
- Affect almost all organ systems of the body
- Generally categorized as Macro vascular and Micro vascular

1. Macro vascular Complications
This complication are cardiovascular & cerebrovascular disease including hypertension myocardial infarction ischemia, stroke & peripheral vascular disease
- Prevention and treatments of modifiable risk factors is recommended (Smoking, obesity & initiation of safe exercise.)

2. Micro vascular Complications involve retina, kidney and nerves
- Are unique to diabetes
- Is characterized by capillary basement membrane thickening
- 3 places where impaired capillary function may have devastating effects are the microcirculation of the retina of the eye (Retinopathy - twenty five times greater risk of blindness) & the kidney (Nephropathy - seventeen
Foot and leg problems

- 50-70% of lower extremity amputations are performed on people with diabetes. 50% of which are preventable, provided patients are taught preventive foot care on daily basis
- Diabetic complications contributing to foot infections are: Neuropathy, peripheral vascular disease and immunocompromised.
  - **Neuropathy**
    A group of disease that affect all types of nerves including peripheral, autonomic and spinal nerves
    - Leading to loss of pain and pressure sensation and autonomic neuropathy
    - Leads to increased dryness and fissuring of the skin (due to increased sweating)
  - **Peripheral Vascular diseases**
    Poor circulation of the lower extremities contributes to poor wound healing and the development of gangrene
  - **Immunocompromised**
    Hyperglycemia impairs the ability of specialized leukocytes to destroy bacteria

Foot Care Instructions for a patient with DM

1. Assess your feet daily for sensation, reddened areas, or broken skin
2. Wash and dry your feet daily, especially between the toes
3. If the skin is dry, apply a thin coat of lubricating oil
4. If callus formation is present, rub areas with a pumice stone when the feet are wet then rub with a towel. Avoid use of chemical agents
5. Immediately after bathing while the toenails are soft, clip the nails straight across, and smooth them to the shape of the toe.
6. Wear shoes and stockings that give room for movement of the toes. Wear shoes with only moderately high heels
7. Tie shoes loosely but firmly
8. If your feet perspire, change shoes and stockings during the day
9. Measures that increase circulation to the lower extremities should be instituted, including
   - Avoid smoking
   - Avoid crossing legs when sitting
   - Protect extremities when exposed to cold
   - Avoid immersing feet in cold water
   - Use socks or stockings that do not apply pressure to the legs at specific sites or constrict.
   - Apply pressure to the legs at specific sites
   - Institute an exercise regimen
10. Use a light when walking at night
11. Do not place feet near sources of heat (e.g. fireplace, heater, hot water bottle, etc.)
12. Wear shoes when outdoors that protect toes and soles of feet from cuts and bruises.
13. Referral to a specialist when necessary.

Nursing Process

The Patient with Newly Diagnosed Diabetic Mellitus

Assessment
   - The history and physical assessment focus on
     - sign and symptom of prolonged hyperglycemia and
     - physical, social and emotional factors that may affect the patient ability to learn and perform diabetes self care activities
   - The patient is interviewed and asked for a description of
1) Symptoms that preceded the diagnosis of diabetes i.e.

- 3ps (polyuria, polydipsia, polyphagia)
- Skin dryness, blurred vision, weight loss, vaginal itching and non-healing ulcer
- The blood glucose and urine ketone (for type I diabetes) level has to be measured

*The patients with type 1 diabetes are assessed for

- Sign of DKA, including ketonuria, kussmaul respiration, orthostatic hypotension and lethargy
- Symptom of DKA—such as nausea, vomiting, abdominal pain
- Laboratory value are monitored for sign of
  - Metabolic acidosis such as
    - PH
    - Bicarbonate
  - Electrolyte imbalance

- Patient with type 2 diabetes are assessed for

  - Signs of HHNK syndrome
    - Hypotension
    - Altered sensorium
    - Seizures
    - Decreased skin turgor

  - Laboratory values are monitored for sign of
    - Hyperosmolarity
    - Electrolyte imbalances
2) Physical factors -that may impair ability to learn or perform self-care skills, or result in complications such as

- Visual deficit
- Deficits in motor coordinator (patient is observed eating or performing other tasks)
- Neurological defect- assessed for aphasia, mental status, sensation in feet

3) Social situation -that may influence the diabetes treatment and educational plan

- Decreased literacy
- Limited financial resource /lack of health insurance
- Presence or absence of family support
- Typical daily schedule

4) Emotional status -is assessed through observation of

  General demeanor- anxiety, withdrawn

  Body language - avoid eye contact

  - Pt asked for major concern and Fear about D.M (this is to see his/her conceptions or identify any misinformation)

  - Coping skill- by asking to patient how to deal with difficult situations

Not all patients may have similar nursing diagnosis because nursing process is client specific and individualized. But possible N/ Dxs include:

Based on the assessment data, the patients major nursing diagnosis may include the following.

- Risk for fluid volume deficit( FVD) related to polyuria  and dehydration
- Altered Nutrition related to ( r/t) imbalance of insulin, food and physical activity
- Knowledge deficit about diabetes self care skills/ information
- Potential self care deficit r/t physical impairment or social factors
Collaborative problem /potential complications

- Fluid over load, pulmonary edema congestive heart failure
- Hypokalemia
- Hyperglycemia and ketoacidosis
- Hypoglycemia
- Cerebral edema

Nursing care Plan

- Attainment of fluid and electrolyte balance
- Optimal control of blood glucose
- Improving nutritional intake and regaining weight loss
- Ability to perform basic diabetic skills and self care activity
- Reduction in anxiety
- Absence of complications

Nursing Interventions

1. Maintaining fluid and electrolyte balance
   - Measuring Intake and output
   - Administering i/v fluid and electrolytes as ordered
   - Encouraging oral fluid intake
   - Monitor lab values of serum electrolyte (esp, Na and k)
   - Vital sign monitoring

2. Improving nutritional intake
   - Diet is planned for the control of glucose
     - Take in to consideration the patients life style, cultural back ground, activity level and food preference
   - Patient is encouraged to eat full meals and snack as based on the kcal need.
   - Arrangement are made with the dietitian for an extra snack before increased physical activities
3. Improving self care

- Patient teaching to prepare for self care
- Special equipment is used for instruction on diabetic injection skill
- Low literacy information is used
- Families are instructed to enable them to assist in diabetic management
  - to profile syringe
  - to monitor blood glucose
- Follow up education is arranged
- Consideration is given for financial limitation or physical limitation (such as center for visually impaired)

Other members of the health care team are informed about variation in the timing of meal and the work schedule (e.g. if pt works at night or in the evening and sleeps during the day / so that the diabetes treatment regimen can be adjusted accordingly.

4. Reducing Anxiety

- Nurse provide emotional support and gives time for client
- Patient and family are assisted to focus on learning self care behavior
- Encouraged to perform the skills that are most feared and reassured and self injection and puncturing a finger for glucose monitoring

5. Patient education and Home care considerations to prevent complications

DM is a chronic life long illness requiring a lifetime of self-management behaviors
- The patient is taught survival skill including

1. Simple pathophysiology
   - Definition
   - Normal blood glucose level
   - Effects of insulin and exercise
   - Effects of food and stress, including illness and infection
B. Treatment modalities
   - Simple pathophysiology
   - Treatment modalities (diet, insulin administration, monitoring BG, Urine ketone)

C. Recognition, treatment, and prevention of acute complications
   - Hypoglycemia
   - Hyperglycemia

D. Pragmatic information
   - Where to buy and store insulin, syringes, glucose monitoring supplies when to call the Nurse or physician.
   - When and how to reach to health unit

In depth / continuing education during follow up

Preventive measures for the avoidance of long-term complications
   - Foot care
   - Eye care
   - General hygiene (of skin care oral hygiene)
   - Risk factor management eg control of BP.

Monitoring and managing potential Complication

1. Fluid over load caused by administration of large volume at a rapid rate
   - This risk is increased in elderly patient and in those with preexisting cardiac disease
   - Nursing care – Monitor the pt closely during treatment for
     ➢ Vital sign at frequent interval
     ➢ Intravenous (IV) in take and keep careful records of l/v and other fluid intake along with urine out put measurement
   - Physical exam with focuses on cardiac rate, rhythm breath sound, venous distension skin torpor and urine output

2. Ortho static hypotension secondary to dehydration
Hypokalemia

- A potential complication (cpx) during treatment of DKA as K is lost from body store

Cause - Dehydration

- Increased urinary excretion of K
- Movement of potassium from extracellular fluid (ECF) into the cell with insulin administration of

Mgt – cautious replacement of potassium

- Ensuring proper kidney functioning before the administration
- Monitoring of cardiac rate, rhythm & electrocardiogram and serum potassium level

3. Hyperglycemia and ketoacidosis

- Monitor blood glucose level and urine ketonuria
- Medication are administered as prescribed
- Pt is monitored for sign and symptom of impending hyperglycemia and ketoacidosis

4. Hypoglycemia

Cause – skip or delay meal

- Not follow the prescribed diet
- Greatly increase the amount of exercise without modifying diet or insulin

Management - Juice or glucose tablet

- Encourage the pt to eat full meal and snacks as prescribed per diabetic diet
- See the above descriptions for the details

5. Cerebral edema

Rare problem, which commonly encountered in children

Evaluation

Expected outcome
1. Achieve fluid and electrolyte balance
   a. Demonstrate I/o balance
   b. Exhibit electrolyte values that are within normal limit
   c. Vital signs remain stable

2. Achieves metabolic balance
   a. Avoid extremes of glucose level (Hpo/hyperglycemia)
   b. Demonstrate rapid resolution of hypoglycemia episode
   c. Avoid further weight loss

3. Demonstrate verbalizes diabetic survival skill
   Simple pathophysiology
   a. Define diabetes as a condition in which high blood glucose is present
   b. State normal blood glucose range
   c. Identifies factors that cause the blood glucose level
      - to fall (insulin, exercise)
      - to rise (food, illness, and infection)
   d. Describes the major treatment modalities
      - Diet
      - Exercise
      - Monitoring
      - Medication
      - Education
   Treatment Modalities (insulin, diet, monitoring, Education)
   a. Demonstration proper technique for drawing up and injecting insulin
   b. Verbalize insulin injection rotation plan
   c. Verbalize understanding of classification of food group
   d. Verbalize appropriate schedule for eating snacks and meals
   e. Demonstrate proper technique – for monitoring blood glucose
Demonstrate proper technique - for disposing of needles used for blood glucose monitoring and insulin injection - for urine ketone testing and verbalize appropriate time to assess for ketones

3.1 Acute Complication (Hypoglycemia and Hyperglycemia)

a. Verbalizes symptoms of hypoglycemia (shakiness, sweating, headache, hunger, Numbness or tingling of lips or finger, weakness, fatigue, difficult concentration, Change of mood and dangers of untreated hypoglycemia (seizure and coma)

b. Identify appropriate Rx of hypoglycemia, including 10 to 15 gm simple Carbohydrate (of 2 to 4 glucose table, 4+6 of juice, 2 to 3 TSP sugar or 6 to 10 life savers) followed by a snack of protein and CHO, such as cheese and cracker or milk or by a regularly scheduled meal

c. Identify potential causes of Hypoglycemia
   i. too much insulin,
   ii. delayed or decreased food intake
   iii. increase physical activity

d. Verbalize preventive behavior i.e monitoring of blood glucose, taking snake before exercises, verbalize importance of wearing medical identification and carrying a source of simple CHO at all time

e. Verbalizes symptom prolonged hyperglycemia- increased thrust and urination

3.2 Pragmatic information

a. Verbalize where to purchase and store insulin, syringe and glucose monitoring supplies
b. Identify appropriate circumstance for calling the physician eg- when ill, when glucose level repeatedly increasing

4. Absence of complication

a. Exhibit normal cardiac rate and rhythm and normal breath sound
b. Jugular venous pressure and distention within normal limit
c. Blood glucose and urine ketones within normal limits
d. Exhibit no manifestation of hypo or hyper glycemia

e. Mental status improved without sign of cerebral edema

f. States measures to prevent occurrence of complications

Keys for the pretest and post test questions for Nurses

1. A
2. C
3. C
4. E
5. A
6. C
7. A
8. C
9. D
10. A- site of injection
    - Preparations of medication
    - Rotations
    - About syringe and needle
    - Some problems with insulin injections

B)- Too much insulin
    - Too little food or
    - Excessive physical exercise
    - Delay of meal or omitting of snacks

C) Sweating
    - Tremor
    - Tachypnea
    - Confusion
    - Seizure
    - Loss of consciousness
D) Having snack, not delaying the meal, right dose of medications, having Candies at hand

F)-assess foot daily for sensation, redness and broken skins
  - Wash dry feet daily
  - If skin is dry apply a thin coat of lubricating oil
  - Tie shoes loosely but firmly
  - If your feet perspire, change shoe and stocking during the day
  - Wear shoe and stocking that gives room for the movement of the toe

Part-ii True or false

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
<th>F</th>
<th>G</th>
<th>H</th>
<th>I</th>
<th>J</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>T</td>
<td>F</td>
<td>T</td>
<td>T</td>
<td>F</td>
<td>T</td>
<td>T</td>
<td>T</td>
<td>T</td>
<td>T</td>
</tr>
<tr>
<td>B</td>
<td>F</td>
<td>L</td>
<td>T</td>
<td>U</td>
<td>T</td>
<td>M</td>
<td>T</td>
<td>N</td>
<td>F</td>
<td>O</td>
</tr>
<tr>
<td>C</td>
<td>T</td>
<td>M</td>
<td>T</td>
<td>N</td>
<td>F</td>
<td>P</td>
<td>T</td>
<td>Q</td>
<td>F</td>
<td>R</td>
</tr>
<tr>
<td>D</td>
<td>T</td>
<td>O</td>
<td>F</td>
<td>P</td>
<td>T</td>
<td>Q</td>
<td>F</td>
<td>R</td>
<td>T</td>
<td>S</td>
</tr>
</tbody>
</table>

REFERENCES

1) Brunner and Sudarths, Text books of Medical-Surgical eight ed. Lippincott company, Philadelphia
2) ì¼R ywYN í/G fiq tÆÆ¶ ßéØsR ½ ySu*R HmM½ /M@ 1995 Ñ¼M
4) 4) Fraces T. Lester, Management of Diabetes Mellitus, 2nd ed., 1991
5) 5) J. Abdulkadir, Diabetic Melitus in Africa.
3.3 SATELLITE MODULE FOR MEDICAL LABORATORY TECHNOLOGISTS

Introduction

1. Purpose of the module

Diabetes mellitus is a diverse group of hyperglycemic disorders with different etiologies and clinical pictures; therefore timely diagnosis and management based on true laboratory results are crucial.

This Satellite Module on Diabetes Mellitus is intended to resolve the critical shortage of clinical chemistry reference materials both for students and for other professionals of the same field working in different health institutions.

1.1 Directions for using the satellite Module

- After completion of the Core Module, try to answer all pre-test questions and write the answers on a separate sheet of paper
- Read the rest of this Satellite Module
- Refer to the Core Module whenever necessary
- Answer the post-test questions
- Compare the results of the pre-test questions with the key given at the end.
2. Pre-test questions

Instructions: choose the appropriate answer from the alternatives given for each question and write the answers on a separate sheet of paper.

1. Why is there a discrepancy between the whole blood glucose concentration and the plasma glucose concentration?
   A. Because there is a different distribution of Glucose in whole blood and plasma
   B. Because there is a high amount of water in plasma
   C. Because the cellular component in whole blood use glucose frequently
   D. None

2. One of the following methods of Glucose determination does use enzymatic reaction
   A. Folin- MU copper Reduction method
   B. Alkaline ferric cyanide method
   C. Hexokinase n.v. method
   D. Somogyi-Nelson method

3. Which one of the following methods is highly specific for glucose determination
   A. Alkaline ferric cyanide method
   B. Copper Reduction method
   C. Glucose oxidase method
   D. O-Toluidine method

4. When does glucose appear in the urine?
   A. When the urine glucose level higher than blood glucose level
   B. When blood glucose level is between 60-110 mg/dl
   C. When the blood glucose level is greater than 180-200 mg/dl
   D. When a person is starved

5. One of the following methods for urinary glucose determination is highly specific
   A. Copper reduction method
   B. O-Toluidine method
   C. Reagent strip Tests
   D. A and B
6. Sodium fluoride additive used in a specimen collected for Glucose
   A. Inhibits glycolytic enzymes from destroying the glucose
   B. Precipitates the protein present in the sample
   C. Prevents non glucose reducing substances from interfering with the testing
   D. None of the above

7. During GGT test in a person with normal glucose metabolism, the blood glucose level usually increases rapidly after carbohydrates are ingested, but returns to a normal level after
   A. 30 minute
   B. 60 minute
   C. 90 minute
   D. 15 minute

8. Which one of the following organs uses glucose from digested carbohydrates and stored it as glycogen for later use as a source of immediate energy by the muscles?
   A. Kidneys
   B. Liver
   C. Pancreas
   D. Thyroid

9. Which one of the following samples good for Glucose determination
   A. Serum/ plasma
   B. Whole blood
   C. Urine
   D. All

10. To say the Oral Glucose Tolerance test is normal
    A. The fasting blood sugar level should be 60-110 mg/dl
    B. The fasting blood sugar level should be higher than 110 mg/dl
    C. The fasting blood sugar level should be normal or slightly elevated
    D. The fasting blood sugar level should be always less than the lower limit.
3. Learning objectives

After studying this satellite module the student will be able to:-

→ Collect, preserve or prepare the correct specimens for diagnosis of diabetes mellitus
→ Perform different clinical chemistry tests in management of diabetes mellitus
→ Practice different quality control procedures in laboratory diagnosis of diabetes mellitus

4. Laboratory tests for diagnosis and management of diabetes mellitus

- Determination of - Blood glucose
  - Serum/ plasma glucose
  - Urine glucose
- Determination of urine ketone bodies
- Determination of urine protein
- Determination of BUN and creatinin

4.1 Types and collection of different sample

Laboratory diagnosis of Diabetes Mellitus may be performed on specimens of:

- Fasting/random whole blood
- Plasma / serum (free of hemolysis)
- Urine

But, serum or plasma is more preferable for the determination of glucose due to the following reasons:

- Since plasma or serum contains approximately 10 to 15% more water than whole blood the total glucose in plasma or serum is about 10 to 15% greater than in whole blood.
- It is easier to interpret values obtained from a single component system (plasma) than a two component system (whole blood)
• Because there are several substances in blood (particularly in red cells) that interfere with tests for blood glucose either because they are measured as glucose or because they interfere in enzyme procedures.

• As indicated above, values based on whole blood tend to vary with the hematocrit.

• Glucose is more stable in plasma or serum than in whole blood, as many glycolytic enzymes are present in RBC.

• Plasma or serum is easier to handle, to pipette precisely and to store than is whole blood.

The blood specimen can be collected both from vein or capillary, it depends on the type of sample the test procedure needs, and if serum or plasma is needed Venus blood should be collected with clean, dry, capped test tube, and with or with out anticoagulant. Urine samples are also possible to collect using, a clean, dry, free of any disinfectant, large and wide mouth container so as to do both qualitative and quantitative determination of glucose and others.

4.2 Types of blood specimen for Glucose determination

4.2.1 Fasting blood specimen
The term fasting in this case means that the patient has had no food or drink for 8 to 12 hours, no drugs that might affect the blood glucose level, and no emotional disturbances that might cause liberation of glucose into the blood.

4.2.2 Two Hours post prandial specimen
A blood specimen drawn 2 hours after a meal is know as a two- hour post prandial specimen. To more completely detect diabetes mellitus, stressing the system with a defined glucose load tests carbohydrate metabolic capacity. To do this, a high-carbohydrate drink or meal is given to the patient, blood is collected 2 hours after ingestion, and the glucose concentration is determined.
4.2.3 Capillary blood specimen

An advantage of using whole blood is the convenience of measuring glucose directly on capillary blood, such as:

- That taken from infants
- In mass screening programs for detection of diabetes mellitus, or
- In the home monitoring being done by so many diabetes patients.

In the fasting state the arterial (capillary) blood glucose concentration is 5 mg/dl higher than the venous concentration.

5. Preparation and preservation Samples for glucose determination

The following factors which affect the stability of glucose in body fluid must be taken into account, such as:

- Those glycolytic enzymes found particularly in the red cells, which undergo glycolysis at an average rate of approximately 10 mg/dl/hr in whole blood or 5 mg/dl/hr in sufficiently centrifuged plasma which still contain leukocytes.

Keeping these considerations in mind, there are several ways to prevent or retard glycolysis in specimen to be analyzed. For example:

- Sample for glucose analysis should be delivered to the laboratory as soon as possible after being drawn from the patient.
- Refrigeration or addition of small amount of sodium fluoride to the fluid may retard glycolysis for a few hours.
- If plasma or serum is to be used for the glucose determination, it must be separated from the cells or it will clot within 30 minutes after the blood is drawn unless a specific additive is used.

**Note** When certain enzymatic glucose methods are used, fluoride anticoagulated blood should not be used, as the fluoride might inhibit the enzyme. Use of serum separator gel tubes, processed as quickly as possible within thirty minutes if possible, is performed for these methods.
6. Diagnostic criteria of DM based on Glucose determination

Fasting and Two-hour postprandial tests when glucose metabolism is being monitored, glucose is commonly determined on fasting blood specimens and on 2-hour postprandial specimens. For non pregnant adults, the fasting serum or plasma glucose concentration should normally be less than 110 mg/dl and the serum or plasma glucose taken 2 hours 140 mg/dl. Including in the new criteria from the expert committee on the diagnosis and classification of Diabetes Mellitus. There are three diagnostic criteria for diabetes Mellitus:

1. A fasting serum or plasma glucose level equal to or greater than 126 mg/dl; or
2. A random blood glucose (blood drawn without considering time since the last meal) equal to or greater than 200 mg/dl, along with symptoms of diabetes (polyuria, polydipsia, and unexplained weight loss),
3. A 2-hour post load glucose level equal to or greater than 200 mg/dl during an oral glucose tolerance test. Impaired glucose tolerance (IGT) is indicated if the fasting glucose is between 110 and 126 mg/dl and one postprandial glucose level is greater than 200 mg/dl.


The various methods for the quantitative determination of glucose can be divided in to three general categories.

- Enzymatic Methods,
- Oxidation Reduction methods, and
- Aromatic amine methods.

Of these, enzymatic methods using hexokinase or glucose oxidase methodology are most commonly used
7.1 Enzymatic methods

Almost all currently used glucose Methods utilize enzymatic techniques. The use of enzymes is a means of achieving absolute specificity in the determination of glucose concentration. The two most widely used automated enzyme glucose methods are based on the enzymes hexokinase and glucose oxidase. Glucose oxidase is also used in the most common manual methods.

7.1.1 Glucose oxidase method

**Sample:** whole blood, serum, plasma, and other body fluids

**Principle:** β-D-glucose in serum (specimen) is oxidized to gluconic acid by a specific enzyme glucose oxidase. When glucose is oxidized proportionally H$_2$O$_2$ is released. In the presence of peroxidase enzyme the released H$_2$O$_2$ reacts with oxygen acceptors like aminophenazene and phenol forming a rose colored quinone rose derivative. The intensity of color is directly proportional to the amount of glucose present in the sample and the absorbance is read at 546nm. The absorbance of test is compared with that of standard. In this procedure uric acid, ascorbic acid and glutathione compete with amino phenazine for H$_2$O$_2$. Urine sample cannot be used directly as urine may contain electrolysis those inhibit enzyme activity

**N.B:** Mutase is added to convert α-D-glucose to β-D-glucose

1. Glucose + H$_2$O $\xrightarrow{\text{hexokinase}}$ Glucose 6-phosphate + ADP

2. H$_2$O$_2$ + aminophenazene + phenol $\xrightarrow{\text{peroxidase}}$ quinone imine (rose)

Glucose oxidase is specific to β-D-glucose so mutase is present to convert α-D-glucose to β-configuration

7.1.2. Hexokinase U.V Method

**Sample:** whole blood, serum, plasma and other body fluids

**Principle:** Glucose is phosphorylated in the presence of ATP by catalytic activity of hexokinase forming glucose 6-phosphate and ADP.
dehydrogenase oxidizes glucose 6-phosphate in the presence of hydrogen acceptor NADP+. Proportionally NADP$^+$ is reduced to NADPH. The amount of formed NADPH is directly proportional to the amount of glucose present in the sample. The absorbance due to NADPH is read at 340nm every minute and change in absorbance of the test is compared with that of the standard.

1. Glucose + ATP $\xrightarrow{\text{hexokinase}}$ Glucose – 6- phosphate + ADP$^+$
2. Glucose-6- phosphate +NADP$^+$ $\xrightarrow{\text{G6PDH}}$ NADPH$^+$ + phosphogluconate

A

A= absorbance due to NADPH$^+
C= \text{Glucose concentration}

C

Fig 1. The relationship between absorbance and concentration

7.2 Oxidation-Reduction Methods

Oxidation methods for blood glucose depend on the fact that glucose contains an aldehyde group as part of its chemical structure. The presence of this aldehyde gives glucose its reducing properties. Other substances in blood also have reducing properties. Some of these non-glucose reducing substances are other sugars and metabolic compounds and materials such as uric acid, creatinine, ascorbic acid, certain amino acids, creatine, and phenol. The oxidation-reduction methods for determining blood glucose differ primarily in the way they handle the non-glucose reduction substances. When the non-glucose reducing substances are removed as part of a glucose determination, the resulting value is called the true glucose value.

7.2.1 Alkaline ferric cyanide method

**Sample:** serum, plasma, and whole blood
**Principle:** In hot alkaline solution ferric cyanide ion is reduced by glucose to ferrocyanide ion. Before reduction the color of ferric cyanide solution is yellow and after reduction it is colorless. The decrease in yellow color is directly proportional to the concentration of glucose present in the sample and the absorbance is taken at 420 nm. This method is not specific for glucose since any reducing substance participates in this reaction.

Glucose + Ferric cyanide $\xrightarrow{Alkaline}$ Ferrous cyanide + Oxidized glucose

$$C_T = \frac{\Delta A_T}{\Delta A_{ST}} \times C_{ST}$$

$\Delta A =$ Absorbance before Reaction minute $\text{Absorbance after reaction}$

7.2.2 Copper Reduction Method.

**Sample:** serum, plasma, whole blood and other body fluids.

**Principle** In hot alkaline solution, glucose readily reduces cupric ions to cuprous ions with formation of mainly cuprous oxide ($\text{Cu}_2\text{O}$). On the addition of phosphomolybdic acid (arsenomolybdic acid) to the reaction mixture the cuprous ions quantitatively reduces molybdic acid to lower oxides of molybdenium which is blue in color. The intensity of blue color is directly proportional to the concentration of glucose present in the sample and the absorbance of the solution is read at 680 nm.

$$C_T = \frac{A_T}{A_{ST}} \times C_{ST}$$

$A_{ST} =$ absorbance of standard
$C_{ST} =$ concentration of standard
$C_T =$ concentration of test
$A_T =$ absorbance of test

This method has many drawbacks:

$\rightarrow$ Lacks specificity due to the reducing ability of uric acid, glutathione and others.
It needs special tubes, constricted follin- MU tubes

It needs color stabilizers, NO₂ SO₄, which prevents reoxidation of Cu⁺

It needs protein precipitants like tungstic acid, Ba (OH)₂ and Zn SO₄

The method is highly sensitive, though it is laborious

Glucose + Cu²⁺ \[\xrightarrow{\text{hot}}\] Cu⁺ oxidized Glucose

\[\text{Cu}^+ + \text{arsenomolybdoc acid} \rightarrow \text{Cu}^{++} + \text{reduced arsenomolybdate}\]

(Blue color)

7.2.3.a. Folin- Mu copper Reduction Method

Reagents

1. Protein free filtrate reagent, aqueous solution
   a. H₂SO₄ ................................. 0.67N
   b. B Na₂O₄.2H₂O ......................100g/l

2. Copper reagent
   a. Na₂CO₃ ..........................40g
   b. Tartaric acid ...................... 7.5g
   c. CuSO₄.5H₂O ...................... 4.5g

To prepare this reagent dissolve Na₂ CO₃ in 500 ml of distilled water. With stirring transfer tartaric acid to Na₂CO₃ solution. CuSO₄.5H₂O is first dissolved in 100 ml of water and transfer the whole solution to Na₂CO₃ – tartaric acid solution with stirring. Dilute the solution to 1000ml. The reagent is stable indefinitely at 20°C.

3. Phosphomolybdic acid reagent
   a. Na₂ WO₂.2H₂O ...............10gm
   b. Molybdic acid (MOO₃) ....70gm
   c. 10%W/v NaOH solution ... 400ml
NaOH solution is added with stirring. Boil the solution for 30-40 minutes and cool to room temperature.

d. Add distilled water to ............ 700ml

e. Concentrated H$_3$PO$_4$ ............. 250ml

f. Dilute the solution to ............ 1000ml

Procedure

Arrange 3 test tubes labeled blank, standard & test

<table>
<thead>
<tr>
<th></th>
<th>RB</th>
<th>ST</th>
<th>T</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose standard 200mg%</td>
<td>-</td>
<td>0.5ml</td>
<td>-</td>
</tr>
<tr>
<td>Water</td>
<td>1.0ml</td>
<td>0.5ml</td>
<td>0.5ml</td>
</tr>
<tr>
<td>Serum</td>
<td>-</td>
<td>-</td>
<td>0.5ml</td>
</tr>
<tr>
<td>0.67 NH$_2$SO$_4$</td>
<td>0.75ml</td>
<td>0.75ml</td>
<td>0.75ml</td>
</tr>
<tr>
<td>10% Na$_2$WO$_4$</td>
<td>0.25ml</td>
<td>0.25ml</td>
<td>0.25ml</td>
</tr>
</tbody>
</table>

Mix and centrifuge. Transfer 1.0 ml of each of the blank, standards and each of filtrate to folin- Mü sugar tubes graduated at the 12ml mark. To the 3 test tubes transfer 1.0ml copper reagent and heat the tubes in a boiling water bath or heating black at 100°C for 8 minutes and cool to room temperature. To each tube transfer 1.0ml of phosphomolybdic acid with Mixing. Dilute the tubes to 12 ml with water and mix. Read the absorbance of the test (T) and standard (ST) against reagent blank (RB) at 680nm.
### 7.2.3.b. Somogyi-Nelson Method

<table>
<thead>
<tr>
<th>Step</th>
<th>Solution Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Zinc sulfate solution</td>
</tr>
<tr>
<td></td>
<td>ZnSO$_4 \cdot 7\text{H}_2\text{O}$ 50 gm</td>
</tr>
<tr>
<td></td>
<td>Water to 1000 ml</td>
</tr>
<tr>
<td>2.</td>
<td>Barium hydroxide solution (0.3N)</td>
</tr>
<tr>
<td></td>
<td>Ba(OH)$_2 \cdot 8\text{H}_2\text{O}$ 50 gm</td>
</tr>
<tr>
<td></td>
<td>Water to 1000 ml</td>
</tr>
<tr>
<td></td>
<td>After 3 days filter and keep in polyethylene bottle</td>
</tr>
<tr>
<td>3.</td>
<td>Copper sulfate solution</td>
</tr>
<tr>
<td></td>
<td>Na$_2$HPO$_4$ 0.29 gm</td>
</tr>
<tr>
<td></td>
<td>K-Na-C$_4$H$_4$O$_6 \cdot 4\text{H}_2\text{O}$ 40 gm</td>
</tr>
<tr>
<td></td>
<td>Water to 700 ml</td>
</tr>
<tr>
<td></td>
<td>1 N NaOH 100 ml</td>
</tr>
<tr>
<td></td>
<td>10% W/V CuSO$_4 \cdot 5\text{H}_2\text{O}$  80 ml</td>
</tr>
<tr>
<td></td>
<td>CuSO$_4$ is added with stirring</td>
</tr>
<tr>
<td></td>
<td>Na$_2$SO$_4$ 180 gm</td>
</tr>
<tr>
<td></td>
<td>Water to 1000 ml</td>
</tr>
<tr>
<td></td>
<td>Let stand for two days and filter and precipitate. Keep at 20-25°C</td>
</tr>
<tr>
<td>4.</td>
<td>Arsenomolybdic solution</td>
</tr>
<tr>
<td>5.</td>
<td>Water 900 ml</td>
</tr>
<tr>
<td>6.</td>
<td>Conc. H$_2$SO$_4$ 42 ml</td>
</tr>
<tr>
<td>7.</td>
<td>Ammonium molybdate 50 gm</td>
</tr>
<tr>
<td>8.</td>
<td>12 gm% W/V sodium arsenate 50ml</td>
</tr>
</tbody>
</table>

Mix and incubate at 37°C for 48 hours. Store in a brown bottle.
Procedure

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>ST</th>
<th>T</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood, serum or CSF</td>
<td>0.5ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td></td>
<td>7.5ml</td>
<td></td>
</tr>
<tr>
<td>Ba (OH)₂</td>
<td></td>
<td>1ml</td>
<td></td>
</tr>
<tr>
<td>Mix and let stand</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>for 1 minute</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZnSO₄</td>
<td></td>
<td>1ml</td>
<td></td>
</tr>
<tr>
<td>Mix and let stand</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>for 2 minutes</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Separate the protein free filtrate from the precipitate. Arrange 3 folin-Mutubes labeled as blank (B), standard (ST) and Test (T).

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>ST</th>
<th>T</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filtrate (ml)</td>
<td>-</td>
<td>-</td>
<td>2.0</td>
</tr>
<tr>
<td>Distilled water (ml)</td>
<td>2.0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Standard (ml)</td>
<td>-</td>
<td>2.0</td>
<td>-</td>
</tr>
<tr>
<td>CuSO₄ solution (ml)</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Mix and incubate the tubes in boiling water both or heating block (at 100°C) for 10 minutes. Cool in cold water by immersing the tubes in cold water bath.

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>ST</th>
<th>T</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arsenomolybdate</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Allow to stand for 2 minute at 20°C and dilute to 25ml with water and measure the absorbance of the standard and test against reagent blank at 490 nm.

\[
CT = \frac{A_T \times CST}{A_{ST}}
\]
7.3 Aromatic amine methods

Aromatic amine methods depend on the fact that various aromatic amine methods depend on the fact that various aromatic amines react with glucose in hot acetic acid to form colored derivatives.

7.3.1 O-Toludine Method

**Sample:** plasma, serum, and other body fluids

**Principle:** Aromatic amines react with glucose in hot acetic acid solution to produce a colored derivative. In this specific method glucose reacts with O-toludine in hot acetic acid and in the presence of thiourea, forming a green colored derivative, which is called shiff- base (glucosylamine). The intensity of color is read at 630 nm and it is directly proportional to the amount of glucose present in the sample.

![Chemical Reaction Diagram]
Reagent

1. O-Toludin reagent
   Thiourea ......................... 1.5gm
   Acetic acid (pure) ............. 940ml
   O-Toluidine ...................... 60ml
   Mix well and keep the solution in brown bottle in the dark at 20°C stable for two months

2. Glucose standard (stock)
   Glucose powder ............... 20gm
   1gm% W/V benzoic acid to ...... 1000ml
   Stable for one year if kept at 4-10°C

3. Glucose working standard
   Glucose stock standard .............. 5ml
   1gm% benzoic acid to ............. 100ml
   Stable for Six months if kept at 4-10°C. Both stock and working glucose standards should be stored (kept) at 4-10°C

Procedure

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>St</th>
<th>T</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distilled water (ml)</td>
<td>0.1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Glucose standard (ml)</td>
<td>-</td>
<td>0.1</td>
<td>-</td>
</tr>
<tr>
<td>Serum (ml)</td>
<td>-</td>
<td>-</td>
<td>0.1</td>
</tr>
<tr>
<td>O-Toluidine reagent (ml)</td>
<td>7</td>
<td>7</td>
<td>7</td>
</tr>
</tbody>
</table>

Mix well and incubate at 100°C for 10 minute. Cool and read the absorbance at 630 nm
In the detection and treatment of diabetes it is sometimes necessary to have more information than can be obtained from only testing the fasting specimen for glucose. Therefore the GTT is usually performed:

- When a person has been found to have a fasting serum or plasma glucose concentration above that of most non diabetic persons (about 110 mg/dl)
- To identify hypoglycemia, an abnormal response to a glucose load that results in a serum or plasma glucose concentration much below the normally accepted range

Since early detection and management of diabetes are important to avoid the many complications of the disease, it is desirable to detect these early cases of diabetes or pre diabetes. For these reasons, the physician may request a glucose tolerance test.

**a. Oral glucose Tolerance Test.**

To conduct oral glucose tolerance test on a subject, first blood and urine samples are taken in fasting state, and, the blood glucose level is determined. The urine sample is qualitatively tested for glucose. If blood glucose level is normal and urine sample is negative the individual will be loaded with 75 gm glucose dissolved in 300 ml of water. Blood and urine samples are collected every 30 minutes four times for a period of 3 hours. The blood sample are analyzed for glucose concentration and the urine samples are qualitatively tested for glucose.
Note: In malabsorption of carbohydrate the fasting blood glucose level is always less than the lower limit of the normal range. During GTT, blood glucose level will not rise even with in 2 hours, above the normal range. Most probably slight elevation may be observed after 3 hours then falls down below the normal range with in one or one half hours

b. Intravenous Glucose Tolerance Test: this method is less commonly used, although it eliminates the variable factors involved in the rate of intestinal absorption in different individuals. 0.5g. Glucose is given per kg body weight by infusing 20gm% W/V glucose solution and the infusion will be completed with in half an hour. In normal individuals the blood glucose concentration does not rise to more than 250 mg% at the end of infusion and falls below the fasting level with in 2 hours. In case of latent and severe diabetes mellitus glucose concentration pattern will be as in oral GTT.

Factors affecting (altering) carbohydrate tolerance

1. Quantity of glucose administered: The peak level doesn’t increase if the quantity of glucose administered is greater than 50 gm, since glucose is absorbed at a steady rate by the intestine and it may take a longer time to return to fasting level even in normal GTT.

2. The rate of absorption may be low in conditions of mal absorption and high in hyperthyroidism. This may result in low peak level or an early high peak.

3. Diet preceding the day of test: Starvation or carbohydrate free diet will decrease the carbohydrate tolerance of the individual and cause hyperglycemia and glycosuria when the individual is subjected to GTT. Therefore, in order to get the correct diet of the carbohydrate tolerance (GTT) the subject must be on a carbohydrate diet for preceding 3 days

4. Age: Elderly people show a decrease carbohydrate tolerance

5. Endocrine: Insulin increases carbohydrate tolerance while all other hormones considered earlier tend to decrease its tolerance.
8. Self-Monitoring of glucose

Many patients (especially those with type 1 (insulin-dependent diabetes mellitus)) now regularly monitor their own blood glucose concentrations on the advice of their health care provider, using reagent test strips and reflectance meter. Several companies manufacture reagent test strips for monitoring blood glucose, and most of these companies make reflectance meters to be used to electronically read the test result. Instruments include one Touch,* Accu-check Easy, and Glucometer Elite. The strips used for these tests are impregnated with the enzyme glucose oxidase, enzyme peroxidase and an indicator to give a color change that is detectable. The color change can be read in a reflectance meter on which the result (in mg/dl) is visualized. Although blood is tested, results are converted to plasma glucose values by the instrument.

Eg. Glucose oxidase reaction (Vitros Method)

\[
\text{Ex } \beta - \text{D-glucose} + \text{H}_2\text{O} \xrightarrow{\text{glucose oxidase}} \text{D-gluconic acid} + \text{H}_2\text{O}_2
\]

\[
2\text{H}_2\text{O}_2 + 4 \text{aminopyrine} + 1,7\text{-dehydroxynaphthylene} \xrightarrow{\text{peroxidase}} \text{H}_2\text{O} + \text{a red dye}
\]

9. Urine Glucose determinations

Chemical screening tests for glucose (dextrose) are generally included in every routine urinalysis. The occurrence of glucose in the urine indicates that the metabolic disorder diabetes mellitus should be suspected, although several other conditions result in glycosuria (glucosuria).

The lowest blood glucose concentration that will result in glycosuria is termed the renal threshold (180-200 mg/dl). It is possible to use both enzymatic technique and oxidation-reduction technique to determine urine glucose.
9.1 Enzymatic technique

9.1.1 Reagent strip (Glucose oxidase) Tests

Principle and specificity
Since the reagent strip tests for urinary sugar use glucose oxidase which only react in the presence of glucose they are highly specific. Reagent strip tests for urine glucose are double sequential enzyme reactions. Glucose oxidase will oxidize glucose to gluconic acid and at the same time reduce atmospheric oxygen to $\text{H}_2\text{O}_2$. The hydrogen peroxide formed will, in the presence of the oxidized form, which is indicated by the color change of an oxidation-reduction indicator.

**Step 1:**

\[
\text{Glucose} + \text{O}_2 \xrightarrow{\text{Glucose oxidase}} \text{Gluconic acid} + \text{H}_2\text{O}_2 \\
\text{(In urine)}
\]

**Step 2**

\[
\text{H}_2\text{O}_2 + \text{Reduced Proxidase oxidized form of dye} + \text{H}_2\text{O} \\
\text{Form of dye}
\]

Note: The glucose oxidase, peroxidase and the reduced form of the Oxidation-Reduction indicator are all impregnated on to a dry reagent strip. There are different kinds of reagent strips and they all contain Glucose oxidase and peroxidase.

**9.1.1.1 Procedure**

1. Collect the urine sample with a clean, dry, free from any antiseptic and wide mouth container
2. Transfer the urine into a conical test tube
3. Take one strip from the reagent strip container
4. Immerse the strip into the urine in a conical test tube
5. Immediately pull it out and let it stand for one minute. So as to have time for reaction and color change to occur on the strip
6. After one minute read the result by matching the color on the strip with the color on the reagent strip container.

7. Report the result.

**9.1.1.2 Interferences**

False – positive results can occur due to:
- Contamination by bleach or other strong oxidizing agents
- Trace values may be seen in very dilute urine specimens, because of increased sensitivity at low specific gravity
- When the strip is exposed to air

False-negative or delayed results
- Large urinary concentration of ascorbic acid
- Sodium fluoride is an enzyme inhibitor
- Refrigerated specimens, because of decreased enzyme activity

**9.2 Oxidation reduction technique**

**9.2.1 Clinitest copper reduction test for reducing sugars.**

**Principle:** The clinitest tablet test is a non specific test for urinary sugar, which utilizes the ability of glucose (or any reducing substance) to reduce copper II (cupric) ion to copper I (cuprous) ions, in the presence of heat and alkali. A positive reaction is semiquantitated as a change in color ranging from blue to green, yellow, and orange, depending on the amount of sugar present.

$$2\text{CuSO}_4 + \text{Reducing substance} \xrightarrow{\text{alkali, heat}} \text{Cu}_2\text{O} \text{(copper)} + \text{oxidized from of} \quad \text{(glucose) \quad \text{heat} \quad \text{reduction substance} \quad \text{gluconic acid)}$$
The reaction is essentially Benedict’s qualitative test for urine sugar in a solid form. The tablet combines:

- Copper sulfate
- Anhydrous sodium hydroxide
- Citric acid and
- Sodium carbonate in an effervescent tablet

The interaction of sodium hydroxide with citric acid and water results in moderate boiling, making an external boiling water bath unnecessary.

### 9.2.1.1 Procedure for clinitest Tablet test

- Place five drops of urine in a 15x85 mm test tube and add ten drops of water
- Add one clinitest tablet
- Watch while boiling takes, but do not shake
- Wait 15 seconds after boiling stops, then shake the tube gently, and compare the color of the solution with the color scale supplied.
- Report results with the same units as used for reagent strip glucose result (mg/dl or g/dl)
- Watch the solution carefully while it is boiling if it passes through orange to a dark shade of greenish brown, the sugar concentration is more than 2 g/dl and the result should be recorded as greater than 2 g/dl without reference to the color scale.

### Specificity

Copper reduction tests such as clinitest are non-specific tests for reducing substances (sugars). The glucose is acting as reducing agent, and any compound with free aldehyde or ketone group will give the same reaction.

### Sensitivity

Clinitest reagent tablets will detect as little as 250 mg/dl sugar (0.25 g/dl) This is less sensitive than the reagent strip tests for glucose.
9.2.1.2 Interferences

False positive results occurs:

- Since it is reducing substance, the presence of extremely large amount of ascorbic acid
- Specimens that have a low specific gravity and contain glucose may give slightly elevated result
- Large quantities of nalidixic acid, cephalosporins and probenacid.

False negative results

- Mixing the test tube before the 15 second wait after boiling stops, due to reoxidation of the cuprous ions to cupric ions by atmospheric oxygen

10. Determination of ketone bodies in urine

Ketone bodies are a group of three related substances: acetone, aceto acetic acid, and β–hydroxyl butyric acid. When ever fat (rather than carbohydrate) is used as the major source of energy, ketosis and ketonuria may result. The two outstanding causes of ketone accumulation are diabetes mellitus and starvation. In diabetes mellitus, the body is unable to use carbohydrate as an energy source and attempts to compensate by resorting to fat catabolism, which results accumulation of ketone more than normal, that the body is unable to utilize it. The clinical result is an increased concentration of ketones in the blood (ketonemia) and in the urine (ketonuria.) Since the presence of ketone bodies in urine is an early indication of lack of adequate insulin control, reagent strips that combine tests for glucose and ketone are often used.

10.1 Dipstick test

Principle: the reagent strip tests for ketone bodies are based on legal’s (Rothera’s) test, a color reaction with sodium nitroprusside (nitro ferricyanide). Acetic acid will react with sodium nitro prusside in an alkaline medium to form a purple color.
10.1.1 Procedure
1. After collecting the urine sample from the patients, transfer into a clean, dry and free of disinfectant test tube
2. Then immerse the dipstick into the urine
3. Then drain and let it stand for certain seconds for the reaction to take place
4. Read the result by comparing the color produced with the standard on the strip container

Note acetone and acetoacetic acid can be detected by different dip stick tests, but there is no reagent strip test for β-hydroxy butyric acid

10.1.2 Interferences
- The presence of various:
  • Pigments
  • Drugs or
  • Urine specimens presents problems in reading results
- False-positive may result due to:
  • Specimens containing phthaleins, very large amounts of phenyl ketones or the preservative β-hydroxy quinoline
  • Highly concentrated urine specimens
- False-negative
  • Conversion of acetoacetic acid to acetone with subsequent evaporation from the specimen in improperly stored urine specimen.

11 Determination of urine protein

Microalbuminuria
- Diabetes mellitus causes progressive changes to the kidneys and ultimately results in diabetic renal nephropathy. This complication progresses over a period of years and may be delayed by aggressive glycemic control
- An early sign that nephropathy is occurring is an increase in urinary albumin
- It is thought that the early development of renal complications can be predicted by the early detection of consistent microalbuminuria. And this early detection is
desirable, as better control of blood glucose levels may delay the progression of renal disease

11.1 Methods of measurement

Test for urinary protein are of two major types:

a. Tests that are based on the use of the protein error of PH indicators
   - This is the methodology employed in the various reagent strip tests
   - They are more sensitive to the presence of albumin than to other proteins.

b. Tests that are based on the precipitation of protein by chemical or coagulation by heat
   - This test will detect all proteins, including albumin, glycoproteins, globulins, Bence Jones protein & hemoglobin

11.1. a Reagent strip test

Principle: Reagent strip tests for urinary protein involves the use of PH indicators substances that have characteristic colors at specific PH values. The phenomenon of showing different color at different PH is called “The protein error of indicators”. The PH of the urine is held constant by means of buffer, so that any change of color of the indicator will indicate the presence of protein.

11.1.a.1 Procedure
It is the similar with other reagent strip test procedure. (But the reading time can vary manufacture to manufacturer instruction on the leaf late)

Specificity
The reagent strip tests for urinary protein are more sensitive to the presence of albumin than they are to other proteins
Sensitivity (minimum Detectable level:)
Manufacturer’s value
- Multistrix / Albustix………………………..15 to 30 mg/dl albumin
- Chemstrip……………………………. 6 mg/dl albumin
- Etc

11.10.2 Interferences
- If the urine is strongly pigmented, there may interference with the color reaction.

False- positive results
- If the urine is exposed to the reagent strip for too long, the buffer may be washed out of the strip, resulting in the formation of blue color whether protein is present or not
- If a urine specimen is exceptionally alkaline or highly buffered, the reagent strip tests may give a positive result in the absence of protein

False – Negative results
- When proteins other than albumin are present, the reagent strip will give a negative result in the presence of protein

11.1. b. Confirmatory tests (sulfosalicylic acid (SSA) test
SSA test or another protein precipitation method may be used to confirm the presence of protein when reactions indicating a trace or more are obtained or when reagent strip results are in doubt.

SSA test
Principle: This test is based on the cold precipitation of protein with a strong acid, namely sulfosalicylic acid.

11.1b.1 procedure for SSA test for urine protein
- Centrifuge a 12 ml aliquot urine
• Decant 11 ml of the supernatant urine into a 16x125 mm test tube. Note the clarity of the centrifuge urine
• Add 3 ml of 7g/dl sulfosalicylic acid reagent
• Stopper the tube and mix by inverting twice
• Let stand exactly 10 minutes
• Invert tube twice
• Observe the degree of precipitation and grade the results
• To observe the degree of precipitation, tilt the test tube while simultaneously viewing the quality and quantity of precipitate in the mirror

Table shows SSA protein test result

<table>
<thead>
<tr>
<th>SSA result</th>
<th>Description</th>
<th>Approximate protein concentration in mg/dl</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>- No turbidity, or no increase in turbidity, clear ring is visible at bottom of tube when viewed from above</td>
<td>&lt;5 mg/dl</td>
</tr>
<tr>
<td>Trace</td>
<td>- Barely perceptible turbidity, in ordinary room light printed material distorted but readable through the tube can not see a ring at bottom of tube when viewed from above</td>
<td>5-20 mg/dl</td>
</tr>
<tr>
<td>+1</td>
<td>Distinct turbidity but no distinct granulation</td>
<td>30mg/dl</td>
</tr>
<tr>
<td>2+</td>
<td>- Turbidity with granulation but no flocculation</td>
<td>100mg/dl</td>
</tr>
<tr>
<td>3+</td>
<td>Turbidity with granulation and flocculation</td>
<td>300-500 mg/dl</td>
</tr>
<tr>
<td>+4</td>
<td>- Clumps or precipitated protein or solid precipitate</td>
<td>&gt; 500mg/dl</td>
</tr>
</tbody>
</table>

11.1b.2 Interference
False-positive results
- Turbidity (cloudiness) in the urine specimen. Urine must be clarified before testing
False- Negative results

- The occurrence of highly buffered alkaline urine if the buffer is sufficient to neutralize the acid in SSA.

12. Determination of creatinine and BUN

Diabetes mellitus can have profound effects on the renal system. In insulin-dependent diabetes mellitus (IDDM, type I) patients suffer from a deficit of insulin activity. Approximately 40% to 50% of these patients will develop progressive deterioration of kidney function (diabetic nephropathy) within 15 to 20 years after their diagnosis.

The lesions are primarily glomerular, but they may affect all other kidney structures as well, they are theorized to be caused by the abnormally hyperglycemic environment than constantly bathes the vascular system. In this case we will do a renal function tests, such as

- Determination of blood and urine creatinine
- Determination of Blood urea nitrogen & urea

12.1 Determination of blood urea nitrogen and urea

It is customary, in most laboratories, to express urea as BUN, but urea is quite different from BUN. The structure of urea is \( \text{NH}_2\text{-CO-NH}_2 \) having a molecular weight of 60. The two nitrogen atoms represent 28. Therefore urea represents 28 gm urea nitrogen (BUN), or 2.14 gm urea stands for 1gm BUN. BUN is converted to urea by multiplying the value of BUN by 2.14 and urea is converted to BUN by dividing the value of urea by 2.14

12.1.1 Determination of urea

There are two methods, such as:-

12.1.1.1 colorimetric methods for urea determination

eg. Bertholet method

12.1.1.2 U.V enzymatic method in urea determination
Bertholet method

Specimen: serum, plasma, urine and other body fluid

Principle: urea is hydrolyzed to \( \text{NH}_4\text{HCO}_3 \) by urease enzyme at \( 37^\circ\text{C} \). The released \( \text{NH}_4\text{HCO}_3 \) is converted to \( \text{NH}_3, \text{CO}_2 \) and \( \text{H}_2\text{O} \) by making the reaction mixture alkaline. This \( \text{NH}_3 \) reacts with phenol in the presence of sodium hypochloride and sodium nitroprusside SNP (catalyst). The reaction product is a blue colored derivative indophenol. The intensity of blue color is directly proportional to the concentration of urea present in the sample and the absorbance is read at 560 nm and compared with the standard.

\[
\begin{align*}
1. & \quad \text{NH}_2\text{C}=\text{NH}+ 2\text{H}_2\text{O} \xrightarrow{\text{urease}} (\text{NH}_4)_2 \text{CO}_3 + \text{H}^+ \\
2. & \quad 2\text{NH}_4^+ + \text{NaOH} \rightarrow 2\text{NH}_3 + \text{H}_2\text{O} \\
3. & \quad \text{NH}_3 + 2 \xrightarrow{\text{NaOCl, SNP}} \text{Indophenol} \\
\end{align*}
\]

SNP = sodium nitroprusside

Reagents

<table>
<thead>
<tr>
<th>1. Urease buffer, ( \text{pH} ), 6.5</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Urease powder 300,000 IU</td>
<td>15 mg</td>
</tr>
<tr>
<td>EDTA powder</td>
<td>100 mg</td>
</tr>
<tr>
<td>Water to</td>
<td>100 ml</td>
</tr>
</tbody>
</table>

Before making the volume to 100 ml adjust the \( \text{pH} \) to 6.5. The reagent is stable for six months at 4-10\(^\circ\)C

<table>
<thead>
<tr>
<th>2. Phenol reagent</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenol</td>
<td>50 g</td>
</tr>
<tr>
<td>Sodium nitroprusside</td>
<td>250 mg</td>
</tr>
<tr>
<td>Distilled water to</td>
<td>1000 ml</td>
</tr>
</tbody>
</table>
If it is stored in brown bottles at 4-10°C the reagent is stable for two months.

### 3. Alkaline hypochlorite reagent,

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NaOH pellets</td>
<td>25g</td>
</tr>
<tr>
<td>Sodium hypochlorite (NaOCl) or</td>
<td>2mg</td>
</tr>
<tr>
<td>Purex bleach</td>
<td>20 ml</td>
</tr>
<tr>
<td>Distilled water to</td>
<td>1000 ml</td>
</tr>
</tbody>
</table>

N.B If NaOCl is not available use 20 ml purex bleach (10%)

### Urea standard

Stock standard- Dissolve 1.0717 gm pure urea in about 50 ml of distilled water in 100 ml volumetric flask. Add 0.1 gm sodium azide as preservative. Make the volume to 100 ml with ammonia free distilled water. This stock standard provides you 500 mg BUN per 100 ml and 1.072 gm urea/100 ml.

Working standard- 50mg/100 ml BUN or 107.2 mg/100 ml Urea. Dilute 10ml of stock standard to 100ml using ammonia free water.

### Procedure

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>S</th>
<th>T</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urea Buffer (ml)</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Distilled water (µl)</td>
<td>20</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Urea working standard (µl)</td>
<td>-</td>
<td>20</td>
<td>-</td>
</tr>
<tr>
<td>Serum/plasma (µl)</td>
<td>-</td>
<td>-</td>
<td>20</td>
</tr>
</tbody>
</table>

Mix well and incubate at 37°C for 15 min

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>S</th>
<th>T</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenol reagent (ml)</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Alkaline hypochlorite (ml)</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
</tbody>
</table>

If the reagent is stored at 4-10°C in brown bottles it is stable for two months. Mix well and incubate at 37°C for 15 minute. Read the absorbance of the tests and standard at 560 nm against reagent blank.
Calculation

a. For serum
\[ CT = C_s A_T = \text{mg/100ml} \]

b. For 24 hour urine volume in ml
\[ V = 24 \text{ hrs. urine} \]
\[ CT = C_s A_T \times \text{dilution factor} \times v = \text{gm/s4 hrs} \]

Normal values for both sexes

<table>
<thead>
<tr>
<th></th>
<th>Serum/ plasma</th>
<th>24 hours urine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BUN</strong></td>
<td>7.18 mg/100ml</td>
<td>12-20 gm/24 hrs</td>
</tr>
<tr>
<td><strong>Urea</strong></td>
<td>13-45 mg/100ml</td>
<td>25-58 gm/24 hrs</td>
</tr>
</tbody>
</table>

12.1.1.2 U.V enzymatic method

**Sample:** serum, plasma, urine

**Principle:** urea present in the sample is hydrolyzed to \( \text{NH}_4^+ \) and \( \text{CO}_2 \) by catalytic activity of urease enzyme at 37\(^\circ\)C. The released \( \text{NH}_4^+ \) is coupled with \( \alpha-\)ketoglutarate, in the presence of co-enzyme NADH, which is catalyzed by an enzyme glutamate dehydrogenase (GLDH). The reaction products are glutamate, NAD\(^+\) and H\(_2\)O.

1. \( \text{Urea} + \text{H}_2\text{O} \xrightarrow{\text{Urease}} 2 \text{NH}_3 + \text{CO}_2 \)
2. \( 2 \text{NH}_3 + \alpha-\text{ketoglutarate} + \text{NADH} \xrightarrow{\text{GLDH}} 2 \text{Glutamate} + 2\text{H}_2\text{O} + 2\text{NAD}^+ \)
In this reaction NADH is converted to NAD$^+$, and the amount of NADH consumed is directly proportional to the amount of urea present in the sample. The decrease in concentration due to NADH is read at 340 nm every minute. Decrease in absorbance per minute is directly proportional to the concentration of urea present in the sample. For 5 consecutive minutes the absorbance is taken. Change in absorbance is calculated. The average change in absorbance is evaluated

$$CT = \frac{\Delta A_T x C_{st}}{\Delta A_{st}}$$

12.1.2 Determination of creatinine

Specimen: plasma, serum, urine, whole blood and other body fluids can be used

Stability: creatinine is stable in serum and urine for a few days at 4-10°C and for a longer period if the sample is frozen.

12.1.2.1 Method: Jaffe Reaction

Principle: Creatinine present in a protein free filtrate or diluted urine reacts with alkaline picrate forming a golden-brown color of a tautomer of creatinine picrate. The intensity of the golden brown color is directly proportional to the concentration of creatinine present in the sample and the absorbance is read at 550nm.

Calculation

a. For serum

$$CT = \frac{A_T x C_{st} x \text{dilution factor}}{A_{st}}$$

= mg/100ml

b. For urine

$$CT = \frac{A_T x C_{st} x \text{dilution factor} x V}{A_{st} 100,000}$$

= gm/24 hours
V = Total 24 hours urine volume

Normal ranges

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum- Creatinine</td>
<td>0.7-1.6mg%</td>
<td>0.4-1.2 mg%</td>
</tr>
<tr>
<td>Serum creatine</td>
<td>0.2 - 0.5 mg%</td>
<td>0.4-0.9 mg%</td>
</tr>
<tr>
<td>Urine – Creatinine</td>
<td>1.0-2.0 gm/day</td>
<td>0.5-1.8gm/day</td>
</tr>
<tr>
<td>Urine - Creatine</td>
<td>0-40mg/ day</td>
<td>0-0.8 mg/day</td>
</tr>
</tbody>
</table>

Reagents

1. Picric acid (C₆H₃N₃O₇)- 0.04 mole/L
2. NaOH-0.75 mole/L or 30g/L
3. Creatinine standard
   a. Stock: Dissolve 100 mg of pure creatinine in 100 ml of 0.1 N HCL which gives 100 mg/dl
   b. Working- Dilute 2 ml of stock standard to 100 ml of solution using 0.1N HCL to get 2 mg/dl creatinine
4. H₂SO₄ ...................... 0.33 mole/L
5. Sodium tungstate....... 5.0 gm/100 ml
Dissolve 50 gm Na₂WO₄.2H₂O in 700 ml of water and dilute to 1000 ml with water

Procedure

Transfer 1 ml of sodium tungstate, 1 ml of 0.33M H₂SO₄., and 1 ml of water to 1 ml of serum (or plasma). Mix well and centrifuge. Urine is diluted to 1:400. If there is proteinuria treat urine samples as in case of serum and dilute the protein free filtrate (PFF) 1:100. Separate the PFF and arrange the test tubes as follows:
Blank Test Standard

<table>
<thead>
<tr>
<th></th>
<th>Blank</th>
<th>Test</th>
<th>Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distilled water (ml)</td>
<td>4</td>
<td>2</td>
<td>3.5</td>
</tr>
<tr>
<td>Creatinine working standard (ml)</td>
<td>-</td>
<td>-</td>
<td>0.5</td>
</tr>
<tr>
<td>Protein free filtrate of diluted urine (ml)</td>
<td>-</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Picric acid (ml)</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>NaOH solution (ml)</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Incubate at 20-25°C for 15 min., and read the absorbance at 500 nm

A. For serum

\[
CT = \frac{A_T \times C_{st} \times 4}{A_{st}}
\]

B. For urine

\[
CT = \frac{A_T \times C_{st} \times 400 \times 4 \times V}{A_{st} \times 100 \times 1000} = \text{gm/24 hrs}
\]

Quality control

- For producing Laboratory results in determination of different analyst in different clinical samples for the diagnosis of diabetes mellitus and its complications quality control procedures are mandatory practicing

- Commonly to produce correct laboratory results we will control the following factors.

1. Pre analytic factors

This factors are commonly appear before the analysis of the analyte. For example during

103
A. Patient preparation
B. Sample collection
C. Sample handling and storage

A. Patient preparation- during this time a lot of things can be done for example. The patient should be asked about his nutritional status, a recent meal. Alcohol, drugs etc. Which all affect the value of the analyte.

B. Sample collection: During sample collection the laboratory personnel should be aware of the type of sample, time of collection, area of collection (ream or capillary), etc.

C. Sample handling and storage here the type of test tube, anticoagulants and storage temperature with respect to the type of sample should be considered.

2. Analytical factors
The laboratory is more able to control the analytical factors, which depend heavily on instrumentation and reagents

A. Instrumentation
- Instrument function checks that are to be routinely performed should be detailed in procedure manual and their performance should be documented

B. Reagents and kits
Reagents and kits should be dated when received and also when opened. New lots of reagents should be run in parallel with old reagent lots before being used for analysis.

3. Post analytical factors
The post analytical factors consist of the recording and reporting of patient data to the physician with in the appropriate time interval

Post test

Go back to the pretest questions & do them carefully
3.4 SATELLITE MODULE FOR ENVIRONMENTAL HEALTH OFFICERS

1. Direction for using this module
Before reading this satellite module be sure that you have completed the pre-test and studied the core module.

2. Learning objectives
At the end of reading this satellite module the E.H.Os will be able to:
   a. describe the role of environmental health students in DM prevention, controlling and rehabilitative activities.
   b. list the possible environmental predisposing factors of DM.
   c. inspect the sanitation of hospital wards which are dedicated for admitting DM cases and take necessary measures on the defects found.
   d. inspect the working places of DM patients to check whether they are prone to any kind of possible causalities.
   e. educate the community on how to avoid/decrease the predisposing factors DM; chemicals compounds, Biological factors, obesity, sedentary working styles, etc.
   f. educate patients about the controlling and rehabilitative measures of DM cases at the health facilities, at annual DM day, etc.

3. Introduction
Up to the 1950s it was thought and accepted that DM is the headache of public health of the very developed countries. But today literature and statistical data clearly depicted that these cases of diabetes are getting high with alarming incidence rate even in developing nations. And Ethiopia is one of the developing countries where by the prevalence is increasing from time to time.
Numerous environmental events have been proposed to trigger the autoimmune process in genetically susceptible individuals; however, none has been conclusively linked to diabetes.
Identification of an environmental trigger has been difficult because the event may precede the onset of DM by several years. Though this is the case, it is strongly believed that there are environmental factors which have a link with DM like, chemical compounds (Rodenticides, heavy metals virus, rarely exposure to bovine milk proteins), physical factors (penetrative short- wave length rays) etc.

4. Why the pattern of prevalence of DM has changed across the globe?
For this new change of the pattern of prevalence of diabetes many factors were considered as the culprit. Among the factors that aid the increment of the prevalence diabetes even in the developing, countries the following are some:

1. Most people are living in very hectic environment where by the housing condition is predominated with substandard housing condition that doesn’t usually meet the physiological and psychological requirement of the dwellers. And this leads the people to live or to expend much of their time in very stressful environment.

2. People are more ignorant about the healthy style of nutrition at the family and community level in particular and at large respectively. In an area where there is no good understanding about the malnourishment consequences, especially obesity, the high prevalence occurrence of DM in that specific community will be highly inevitable.

3. Long term exposure to some specific type of organic and inorganic chemicals, recently it came to understand that they will cause DM by affecting the pancreas and they interfere with the right physiological secretion of insulin.

4. Exposure to some biological factor (coxsakie and rubella most prominently) cause DM by trigger the autoimmune system so that the destruction of $\beta$ -cell of the pancreas will occur.

5. IN rarest case, DM may happen because of the destruction $\beta$ – cell s of the pancreas by trauma, accidents, chronic inflammation.
6. Many jobs are becoming sedentary rather than exercise/movement demanding and in turn these furnish the ground for the people to become more obese.
7. Physical exercise is not taken as a routine life activity among the people especially living in developing country where the living places are not comfortable to make exercises at continual basis.

5. Environmental factors linked to DM
Putative environmental triggers include viruses (coxsackie and rubella most prominently) early exposure to bovine milk proteins, and Nitrosourea compounds. Epidemiological studies have noted an association between exposure to bovine milk intake and type 1 A DM; studies are ongoing to investigate a possible relationship between exposure to bovine milk and the autoimmune process of type 1 A DM.

6. Diabetes in Africa: some of the factors related to the development of diabetes in Africa include:
- Genetic Factors: Family history
- Environmental Factors: such as infection, dietary changes.
- Chronic calcific pancreatitis, malnutrition and environmental toxins(oral iron overload)
- Thrifty phenotypes and genotypes - NIDDM
- Plenty food - reduced exercise - insulin resistance a sin urbanization
- Low birth weight - fetal malnutrition - reduction of effective Beta cells - NIDDM.

7. Expected tasks to be accomplished by Environmental Health Officers regarding DM prevention, controlling and rehabilitative actions.

1. The environmental health officers will take great share of tasks of advocacy on proper nutrition so that obesity can be attacked.
2. Construction of standard housing with local materials will be advocated and technically commented and regularly inspected by environmental Health officers. Thus the requirements of physiological and psychological health of the dwellers will be met and this consequently will alleviate the potential stressful environment.

3. Environmental health officers technically suggest comments and follow its implementation to make the working places more comfortable. E.g. a DM patient working in steel processing industry is often time advised to wear very thick and laceration proof gloves at any time of working to avoid the incidence of lacerated wound.

4. Working places, institutions, houses will be inspected at continual basis for whether they are comfortable for DM patients or not, and whether they have the culprit factors (predisposing chemicals, especially Rodenticides (vacor), Biological factors (viruses) physical agents (radiations).

5. Enclosing short wave length ray emanating sites with radiation proof construction materials.

6. Promoting personal hygiene for any DM patients as they are most susceptible and potentially be affected with different kinds of secondary skin infections.

7. Routine hospital sanitation inspection will be beneficial in preventing the admitted DM cases from nosocomial infections.

8. Health information promotion regarding DM is the crucial area where the environmental health officers are expected to play a vital role.

9. The environmental health officers are most needed here to apply their expertise knowledge of housing and institutional sanitation, nutrition and food hygiene and safety, environmental chemistry. Organic chemistry and environmental quality control courses in conformity with the preventing and controlling strategies of DM.

10. It has to be emphasized that E.H.Os should have deep concern about safe injection of insulin and proper disposal of used needles. No room should be left for contamination that is allowing the occurrence of secondary infections.
11. The EHOs are expected to be involved in research activities, to examine and analyze the environment for its physical, chemical and biological qualities that will help in modifying the environment to make ideal for DM cases.

12. Give refresher trainings on DM for environmental health technicians and health extension workers from environmental health point of view.

**Post – test**

First try to look and do the pretest again, then keep on attempting the following questions.

1. What situation makes difficult the study of causation of environmental factors and to link conclusively with DM?
2. Why diabetes mellitus patients are most susceptible for different kinds of skin infections?
3. What is the basic reason for the fact that E.H.Os are supposed to be highly concerned to make the working places free of any possible causalities for DM patients?
4. What are the known environmental factors that are thought to cause DM?
5. What parcel of Health information is highly beneficial for the family or community with strong DM history?

**Multiple Questions**

1. DM can be transmitted through the following ways except
   A. Feco-oral route
   B. Aerosol respiration
   C. contact
   D. Unsafe sexual activity
   E. None of the above

2. DM can be caused by one of the following factor except
   A. β- cell affection by autoimmune system
   B. Chemicals
C. Biological agents
D. taking high amount of sugar in the diet
E. None of the above

3. From the following alternatives one can be identified as one risk group to develop Dm except
   A. Obese person
   B. a person with strong DM family history
   C. a person that had > 4 kg body weight during delivery
   D. a person who has married Dm patient
   E. none of the above

4. From the following set of types of rays one possibly could not cause DM compared with others
   A. IR rays
   B. Gamma rays
   C. Beta rays
   D. Radioactive rays
   E. none of the above

5. The main causative agent of DM is
   A. Bacteria
   B. Viruses
   C. Fungus
   D. Parasites
   E. none of the above
SATELLITE MODULE FOR HEALTH SERVICE EXTENSION WORKERS

Introduction
Every nation in the world will have well developed and vividly written national health policy likewise Ethiopia as a country has clear health policy which is intended to be implemented in every corner of the country. This policy is preventive led. Thus, today there has been a strong commitment from the government side to realize the policy and protects the public health. It is one part of the strategies of national health policy to train the health extension workers as a front line community health personnel in the regional health institutions with the intent that after the end of their training they will go near to the community that is rural areas and they fight with the nation public health challenges together with their professional colleagues in the interdisciplinary approach.

Therefore this module will have the great benefit for the health extension workers to know more about and operationally/procedurally to be instructed then what to do about the different aspects of DM in the health station, even more in the community. Moreover the health extension workers will be very much clear on their role the promotive, preventive, therapeutic tasks regarding DM after they have thoroughly read this module.

Purpose of the module
This module is intended to be used by health extension package workers. It provides basic information on different aspects of diabetes so that they participate in early case detection, case management and prevention of complications as front line health workers.

Directions for using the module
Before starting to read this module, please follow the instruction given below.

- Start with the pre-test before going through the core module.
- Use a separate sheet of paper to write your answers.
Objectives

2.3 Learning Objectives

After reading the module, one will be able to

- Explain the importance of diabetes mellitus as a public health problem
- Describe diabetes mellitus, its classification and clinical presentation.
- Outline the diagnostic tests for diabetes mellitus.
- Describe the logic behind appropriately employed treatment.
- Describe the role played by each member of the health center team.
- Describe the overall principles of management.

Diabetes mellitus

Definition

Diabetes Mellitus is a clinical syndrome comprising a heterogeneous group of metabolic diseases that are characterized by chronic hyperglycemia and disturbances in carbohydrate, fat and protein metabolism secondary to defects in insulin secretion, insulin action or both

Types

Type 1 And type 2

CLINICAL FEATURES

Classical symptoms

- Thirst
- Polyuria
- Nocturia
• Rapid weight loss
• Increased susceptibility to infection in patients with uncontrolled diabetes
• Chronic fatigue and malaise

Signs
• Signs related to acute and chronic complications

Possible laboratory tests at Health center & Health post level for the investigation of Diabetics Mellitus

1. Self-Monitoring of glucose

Many patients (especially those with type 1(insulin-dependent diabetes mellitus)) now regularly monitor their own blood glucose concentrations on the advice of their health care provider, using reagent test strips and reflectance meter. Several companies manufacture reagent test strips for monitoring blood glucose, and most of these companies make reflectance meters to be used to electronically read the test result. Instruments include one Touch,* Accu-check Easy, and Glucometer Elite. The strips used for these tests are impregnated with the enzyme glucose oxidase, enzyme peroxidase and an indicator to give a color change that is detectable. The color change can be read in a reflectance meter on which the result (in mg/dl) is visualized. Although blood is tested, results are converted to plasma glucose values by the instrument.

Eg. Glucose oxidase reaction (Vitros Method)

2. Urine Glucose determinations

Chemical screening tests for glucose (dextrose) are generally included in every routine urinalysis. The occurrence of glucose in the urine indicates that the metabolic disorder diabetes mellitus should be suspected, although several other conditions result in glycosuria (glucosuria).
The lowest blood glucose concentration that will result in glycosuria is termed the renal threshold (180-200 mg/dl). It is possible to use both enzymatic technique and oxidation-reduction technique to determine urine glucose.

2.1 Enzymatic technique

2.1.1 Reagent strip (Glucose oxidase) Tests

Principle and specificity
Since the reagent strip tests for urinary sugar use glucose oxidase which only react in the presence of glucose they are highly specific. Reagent strip tests for urine glucose are double sequential enzyme reactions. Glucose oxidase will oxidize glucose to gluconic acid and at the same time reduce atmospheric oxygen to H₂O₂. The hydrogen peroxide formed will, in the presence of the oxidized form, which is indicated by the color change of an oxidation-reduction indicator.

Note: The glucose oxidase, peroxidase and the reduced form of the Oxidation-Reduction indicator are all impregnated on to a dry reagent strip. There are different kinds of reagent strips and they all contain Glucose oxidase and peroxidase.

2.1.1.1 Procedure
1. Collect the urine sample with a clean, dry, free from any antiseptic and wide mouth container
2. Transfer the urine into a conical test tube
3. Take one strip from the reagent strip container
4. Immerse the strip into the urine in a conical test tube
5. Immediately pull it out and let it stand for one minute.
   So as to have time for reaction and color change to occur on the strip
6. After one minute read the result by matching the color on the strip with the color on the reagent strip container
7. Report the result
3. Determination of ketone bodies in urine

Ketone bodies are a group of three related substances: acetone, aceto acetic acid, and β-hydroxybutyric acid. When ever fat (rather than carbohydrate) is used as the major source of energy, ketosis and ketonuria may result. The two outstanding causes of ketone accumulation are diabetes mellitus and starvation. In diabetes mellitus, the body is unable to use carbohydrate as an energy source and attempts to compensate by resorting to fat catabolism, which results in accumulation of ketone more than normal, that the body is unable to utilize it. The clinical result is an increased concentration of ketones in the blood (ketonemia) and in the urine (ketonuria.)

Since the presence of ketone bodies in urine is an early indication of lack of adequate insulin control, reagent strips that combine tests for glucose and ketone are often used.

3.1 Dipstick test

**Principle:** The reagent strip tests for ketone bodies are based on Legal's (Rothera's) test, a color reaction with sodium nitroprusside (nitro ferricyanide). Acetic acid will react with sodium nitroprusside in an alkaline medium to form a purple color.

3.1.1 Procedure

1. After collecting the urine sample from the patients, transfer into a clean, dry and free of disinfectant test tube
2. Then immerse the dipstick into the urine
3. Then drain and let it stand for certain seconds for the reaction to take place
4. Read the result by comparing the color produced with the standard on the strip container

**Note** Acetone and aceto acetic acid can be detected by different dip stick tests, but there is no reagent strip test for β-hydroxybutyric acid.
4. Determination of urine protein

Microalbuminuria

- Diabetes mellitus causes progressive changes to the kidneys and ultimately results in diabetic renal nephropathy. This complication progresses over a period of years and may be delayed by aggressive glycemic control.
- An early sign that nephropathy is occurring is an increase in urinary albumin.
- It is thought that the early development of renal complications can be predicted by the early detection of consistent micro albuminuria. And this early detection is desirable, as better control of blood glucose levels may delay the progression of renal disease.

4.1 Methods of measurement

Test for urinary protein are of two major types:

a. Tests that are based on the use of the protein error of PH indicators
   - This is the methodology employed in the various reagent strip tests
   - They are more sensitive to the presence of albumin than to other proteins.

b. Tests that are based on the precipitation of protein by chemical or coagulation by heat
   - This test will detect all proteins, including albumin, glycoproteins, globulins, Bence Jones protein & hemoglobin

4.1.1 Reagent strip test

Principle: Reagent strip tests for urinary protein involves the use of PH indicators substances that have characteristic colors at specific PH values. The phenomenon of showing different color at different PH is called “the protein error of indicators” The PH of the urine is held constant by means of buffer, so that any change of color of the indicator will indicate the presence of protein.

4.1.1.1 Procedure

It is the similar with other reagent strip test procedure. (But the reading time can vary manufacture to manufacturer instruction on the leaf late)
Complications

- Classified into acute and chronic complications
- Acute complications are
  - Diabetic ketoacidois
  - Nonketotic hyperosmolar state
  - Hypoglycemia
- Chronic complications
  - Affect many organ systems
  - Are responsible for the majority of morbidity and mortality associated with the disease
  - Can be subdivided into vascular and non-vascular complications
  - The vascular complications are further subdivided into
    - Microvascular complications that includes
      - Diabetic retinopathy
      - Diabetic nephropathy
      - Diabetic neuropathy
    - Macrovascular complications
      - Coronary artery disease
      - Peripheral vascular disease
      - Cerebrovascular disease
  - The non-vascular complications are
    - Gastroparesis
    - Sexual dysfunction
    - Skin changes

Therapeutic approach

There are four components of management for diabetes, which is carried by the health extension workers:
- Diet
- Exercise
- Monitoring
I. Dietary Management

Goal: - provision of all the essential food constitutes (eg, vitamins, minerals)
- Achievement and maintenance of reasonable weight
- Meeting energy needs
- Prevention of wide daily fluctuations in blood glucose levels with BGL as close to normal as is safe & practical
- Decrease of blood lipid levels, if elevated

A. Calories

The most important objective in dietary management of DM is control of total calorie intake to attain or maintain a reasonable body weight & control of blood glucose levels.

The general recommendation include consumption of a balanced health diet composed of the following

- 50% to 60% of calories be derived from carbohydrates
- Less than 30% from fat &
- The remaining 10% to 20% from protein

*Food which diabetic should avoid (rapidly absorbed carbohydrate)*

1) Sugar, honey, jam, marmalade & candy
2) Cakes & sweat biscuits
3) Soft drink (Fanta, cocacola etc)
4) Alcohol (Cognac, tej, arki, whisky)

There are alcohols, which are allowed in moderation, that is, less sweat drinks i.e light beer or dry wine (not more than 2drinks for men, 1 drink for females/day). Alcoholic beverage is equivalent to 12 oz beer, 5 oz wine & 1.5 oz spirit. It should be always taken with food.
Foods which diabetic should take with restrictions

A) Foods from grain eg injera, bread, kinche, dabo kolo, kita, atemit
B) Foods prepared from peas, beans, and lentils
C) Potato, sweat potato, kocho, bulla
D) All fruits except lemons & grape fruit
E) Macaroni, pasta, rice

Foods, which diabetics can take freely or with minimal restriction

A) Lean meat & fish
B) Eggs and milk
C) Green leafy vegetables (kale, salad, cabbage)
D) Lemon, grape fruit
E) Tea, coffee, lemon juice without sugar, ambo water, and other mineral water & clear soup
F) Spices pepper, berberi
G) Tomato, pumpkin, carrot, onion and chile pepper

II. Exercise

- Is extremely important in the management of diabetes because of its effect on
  - lowering blood glucose and
  - reducing cardiovascular risk factors
- Lowers blood glucose level by increasing the uptake of glucose by body muscles and by improving insulin utilization
- Pre or post exercise snack may be required to prevent hypoglycemia after exercise
- Patients should be thought to do regular, moderate exercise at the same time (preferably when blood glucose level are at their peak) and in the same amount for at least 30 minutes each day.
- Patient is advised:- to use proper footwear and if appropriate other protective equipment
  - avoid exercise in extreme heat or cold
- inspect feet daily after exercise
- avoid exercising during periods of poor metabolic control.

III. Monitoring of Glucose and Ketones

Blood glucose level and urine for ketone and glucose should be assessed frequently by self or by having follow up in the health unit.

Pt education -about Insulin Injection

- Insulin injections are administered into the subcutaneous tissue
- Equipment: - Insulin
- Short acting insulin is clear in appearance and long acting insulin are cloudy and white
- The long acting must be mixed (gently inverted or rolled in the hands) before use
- Before injection it should have room T° which may require rolling it in the hands or removing it from a refrigerator for a time before the injection
- If a frosted, adherent coating is present, some of the insulin is bound and should not be used

Syringes

should be matched with the insulin concentration
- 1 ml syringes – hold 100 units
- ½ ml syringes – hold 50 units
- 3/10 ml syringes – hold 30 units

Administering the injection

-Avoid use of alcohol for cleansing
- Four main areas
  - Abdomen
  - Arms (posterior surface)
  - Thighs (anterior surface)
  - Hips
Absorption is greatest in abdomen and decreases progressively in the arm, thigh, and hips

**Rotation**
- Rotation of injection site is required to prevent lipodystrophy, localized changes in fatty tissue,

Pt is instructed as: -
1. Do not use a site > once every 4 to 6 weeks
2. Sites should be 1 to 1 ½ inches apart
3. Use all sites in one geographic area, then move to the next area
4. Document site use

**Side effects of insulin injections**
1. Local allergic reactions.
   - in the form of redness, swelling, tenderness, and indurations or a 2 to 4 cm wheal may appear at the injection site 1 to 2 hrs after injection
   - usually occur during the beginning stage of therapy and disappear with continued use of insulin
   - antihistamine will be given 1 hr before injection
   - if alcohol is used to clean the area the skin should be allowed to dry

2. Systemic allergic reaction
   - are rare
   - local skin reaction that gradually spreads in to generalized urticaria
   Treatment:- desensitization, gradually increasing the amount of insulin

3. Insulin lipodystrophy
   - Refers to a localized disturbance of fat metabolism in the form of loss of sc fat and appears as slight dimpling or more serious pitting of sc fat or is the development of fibrofatty masses at the injection site and is caused by the repeated use of injection site
   - if insulin is injected in to scarred areas the absorption may be delayed
   Treatment: Pt should avoid injection on the areas and prevent by rotating
Injection sites

Risk identification

- Those above 45 years of age every three years
- Those with family history of diabetes mellitus (parent or sibling with type 2 diabetes mellitus)
- Obesity as evidenced by BMI ≥ 27Kg/m²
- History of delivering a baby weighing above 4Kg in a lady or previous episode of gestational diabetes mellitus
- Hypertension

Prevention:

- Screening
  - A number of lifestyle modification and pharmacologic agents are suggested to prevent or delay its onset.

High-risk individuals should be encouraged to

- Maintain a normal body mass index
- Engage in regular physical exercise

No specific intervention is proven to prevent type 2 diabetes mellitus.

Role and Task Analysis
<table>
<thead>
<tr>
<th>Learning Objectives</th>
<th>HO</th>
<th>Nurses</th>
<th>Medical Laboratory</th>
<th>Environmental Health</th>
</tr>
</thead>
<tbody>
<tr>
<td>Describe DM</td>
<td>Define DM study the pathogenesis and clinical manifestations</td>
<td>Define DM study the pathogenesis and clinical manifestations</td>
<td>Define DM study the pathogenesis and clinical manifestations</td>
<td>Define DM study the pathogenesis and clinical manifestations</td>
</tr>
<tr>
<td>Understand the diagnostic approach of DM</td>
<td>Study history and physical examination Study diagnostic procedures</td>
<td>Study history and physical examination Study diagnostic procedures</td>
<td>Study history and physical examination Study diagnostic procedures</td>
<td>Study history and physical examination Study diagnostic procedures Study recording and reporting of results</td>
</tr>
<tr>
<td>Describe the global magnitude of the problem of DM and its importance in Ethiopia</td>
<td>Study the epidemiology Study the risk factors</td>
<td>Study the epidemiology Study the risk factors</td>
<td>Study the epidemiology Study the risk factors</td>
<td>Study the epidemiology Study the risk factors</td>
</tr>
<tr>
<td>Study the treatment strategies for DM</td>
<td>Study overall principles of management of DM Study the therapeutic approach</td>
<td>Study overall principles of management of DM Study the therapeutic approach</td>
<td>Study overall principles of management of DM Study the therapeutic approach</td>
<td>Study overall principles of management of DM Study the therapeutic approach</td>
</tr>
<tr>
<td>Learning Objectives</td>
<td>HO</td>
<td>Nurses</td>
<td>Environmental</td>
<td>Laboratory</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------------</td>
<td>----</td>
<td>--------</td>
<td>---------------</td>
<td>------------</td>
</tr>
<tr>
<td>To believe that screening of high risk individuals for DM can reduce the occurrence of clinical DM</td>
<td>✅</td>
<td>✅</td>
<td></td>
<td></td>
</tr>
<tr>
<td>To believe that early detection and management reduces the prevalence of chronic complications</td>
<td>✅</td>
<td>✅</td>
<td></td>
<td></td>
</tr>
<tr>
<td>To believe that FBS is an important investigation in the diagnosis of DM</td>
<td>✅</td>
<td>✅</td>
<td></td>
<td></td>
</tr>
<tr>
<td>To appreciate the relationship between sedentary life style and DM</td>
<td>✅</td>
<td>✅</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Learning Objectives</td>
<td>HO</td>
<td>Nurses</td>
<td>Environment</td>
<td>Laboratory</td>
</tr>
<tr>
<td>---------------------</td>
<td>----</td>
<td>--------</td>
<td>-------------</td>
<td>------------</td>
</tr>
<tr>
<td>Demonstrate methods and techniques of Diabetic patient examination</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Label patients as high and low risk and follow them accordingly</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Manage diabetics related complication</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Identify risk factors</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Develop necessary skills on laboratory investigations</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Follow the standard reporting and recoding technique</td>
<td>perform the appropriate laboratory tests</td>
<td>perform appropriate laboratory tests - Follow the scientific procedures to do the tests - order routine lab investigations</td>
<td>perform the appropriate laboratory tests - Follow the scientific procedures to do the tests</td>
<td>perform the appropriate laboratory tests - Follow the scientific procedures to do the tests</td>
</tr>
</tbody>
</table>

- Follow the scientific procedures to do the tests
REFERENCE

1. Michael L.Bishop, Janet L.Duben-Engelkirk, Edward P.Fody. 3rd ed clinical chemistry; Principles, procedures, correlations
2. M.F. Laker, clinical biochemistry for medical students
3. Jean Jorgenson Linne’, Karen Munson Ringsrud. 4th ed. Clinical Laboratory Science the basic and routine techniques
6. Brunner and Sudarths,Text books of Medical-Surgical eight ed. Lippincott company,Philadelphia
10. Simon R. Page and George M. Hall; Diabetes Emergency and Hospital Management
12. Carpenter, Griggs, Loscalzo; Cecil Essentials of Medicine
Keys for the pretest and post test questions for Nurses

1. A
2. C
3. C
4. E
5. A
6. C
7. A
8. C
9. D
10. a- site of injection
    -preparations of medication
    -Rotations
    -about syringe and needle
    -some problems with insulin injections
b) -too much insulin
    -too little food or
    -excessive physical exercise
    -delay of meal or omitting of snacks
c) -sweating
    -tremor
    -tachypnea
    -confusion
    -seizure
    -loss of consciousness
d) Having snack, not delaying the meal, right dose of medications, having candies at hand
f) -assess foot daily for sensation, redness and broken skins
    -wash dry feet daily
    -If skin is dry apply a thin coat of lubricating oil
-tie shoes loosely but firmly
-If your feet perspire, change shoe and stocking during the day
-wear shoe and stocking that gives room for the movement of the toe

Key For Laboratory Technology

1. B  6. A
2. C  7. C
3. C  8. B
4. C  9. A
5. C  10. A